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Women’s health concerns are generally underrepresented in basic and translational research, but
reproductive health in particular has been hampered by a lack of understanding of basic uterine and
menstrual physiology. Menstrual health is an integral part of overall health because between menarche and
menopause, most women menstruate. Yet for tens of millions of women around the world, menstruation
regularly and often catastrophically disrupts their physical, mental, and social well-being. Enhancing our
understanding of the underlying phenomena involved in menstruation, abnormal uterine bleeding, and
other menstruation-related disorders will move us closer to the goal of personalized care. Furthermore, a
deeper mechanistic understanding of menstruation—a fast, scarless healing process in healthy individuals
—will likely yield insights into a myriad of other diseases involving regulation of vascular function locally
and systemically. We also recognize that many women now delay pregnancy and that there is an increasing
desire for fertility and uterine preservation. In September 2018, the Gynecologic Health and Disease
Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development
convened a 2-day meeting, “Menstruation: Science and Society” with an aim to “identify gaps and
opportunities in menstruation science and to raise awareness of the need for more research in this field.”
Experts in fields ranging from the evolutionary role of menstruation to basic endometrial biology
(including omic analysis of the endometrium, stem cells and tissue engineering of the endometrium,
endometrial microbiome, and abnormal uterine bleeding and fibroids) and translational medicine (imaging
and sampling modalities, patient-focused analysis of menstrual disorders including abnormal uterine
bleeding, smart technologies or applications and mobile health platforms) to societal challenges in health
literacy and dissemination frameworks across different economic and cultural landscapes shared current
state-of-the-art and future vision, incorporating the patient voice at the launch of the meeting. Here, we
provide an enhanced meeting report with extensive up-to-date (as of submission) context, capturing the
spectrum from how the basic processes of menstruation commence in response to progesterone
withdrawal, through the role of tissue-resident and circulating stem and progenitor cells in monthly
regeneration—and current gaps in knowledge on how dysregulation leads to abnormal uterine bleeding
and other menstruation-related disorders such as adenomyosis, endometriosis, and fibroids—to the clinical
challenges in diagnostics, treatment, and patient and societal education. We conclude with an overview of
how the global agenda concerning menstruation, and specifically menstrual health and hygiene, are
gaining momentum, ranging from increasing investment in addressing menstruation-related barriers facing
girls in schools in low- to middle-income countries to the more recent “menstrual equity” and “period
poverty” movements spreading across high-income countries.
Key words: abnormal uterine bleeding, adenomyosis, endometrium, fibroids, menstrual health,
microbiome, pelvic health menstrual effluent, period poverty, stem cells, tissue engineering, uterus

Related editorial, page 617.

Introduction
Twenty-five years have passed since the National Institutes of Health (NIH) mandated that women and
minorities be included in all government-funded clinical studies unless their exclusion could be justified.
Clearly, this policy has led to numerous women’s health research programs. However, women and
women’s health concerns continue to be underrepresented in research. Most recently, the 2019–2023
Trans-NIH Strategic Plan for Women’s Health Research was initiated to improve the health of women by
advancing rigorous research relevant to advancing women’s health, including sexual and reproductive
health (SRH). Despite focused initiatives such as these, diagnostic development for improving women’s
reproductive health has been hampered by a lack of understanding of basic uterine and menstrual
physiology. A PubMed search of the term “menstruation” yielded less the 1000 publications between 1941
and 1950, followed by a peak of more than 6000 publications between 1971 and 1980 (note: Our Bodies,
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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Ourselves, a book addressing women’s health topics, including menstruation and birth control, was
published in 1973), and then a stable trough with less the 4000 publications per decade over the past 3
decades spanning 1991 through 2019 (Figure 1, A). By contrast, a PubMed search of the term “menstrual
blood” yielded 1 publication during 1941–1950, followed by a steady increase over time to more than 400
publications in the last decade (Figure 1, B). For reference, PubMed searches of “peripheral blood” and
“semen” yielded almost 100,000 and 15,000 publications, respectively, over the past decade.
Glossary of terms
16S rRNA gene: Encodes a component of the 30S small subunit of a prokaryotic ribosome. 16S rRNA
gene sequencing is used for phylogenetic studies because its presence is highly conserved among
bacteria, but its sequence is species-specific.
Aromatase: An enzyme that transforms androgens into estrogens.
AUB: Abnormal uterine bleeding.
Biomass: Amount of living biological organisms in a given niche or ecosystem at a given time. The
upper genital tract has a significantly lower amount of bacterial DNA than other human microbiomes
and is therefore considered a low biomass microbiota.
BMP-2: Bone morphogenetic protein 2.
COEIN: Coagulopathy, Ovulatory, Endometrial, Iatrogenic, Not otherwise classified.
Community state types (CST): Profile that defines the total bacterial community of a given body site
based on the relative abundances of each bacterium. The human vaginal microbial communities were
classified into 5 groups. Specifically, CSTs I, II, III, and V are dominated by L. crispatus, L. gasseri,
L. iners, and L. jensenii, respectively, whereas CST IV has higher proportions of strictly anaerobic
organisms.
DCE-MRI: Dynamic contrast enhanced-MRI.
Diversity (Beta diversity): Refers to the change in the number of taxa detected in 2 or more
ecosystems. It is usually expressed as the total number of species that are unique to each of the
ecosystems being compared.
Dysbiosis: Shift in the physiologic microbiota resulting in an imbalance between commensal and
pathogenic bacteria. Changes in microbial composition owing to the gain or loss of the community
members or changes in the relative abundance of microbes may contribute to the initiation and/or
persistence of many diseases.
Epigenetics: Heritable phenotype changes without changes in genotype (DNA).
Estrobolome: Represents the aggregate of enteric bacterial genes whose products are capable of
metabolizing estrogens. Microbes in the estrobolome produce beta-glucuronidase, an enzyme that
deconjugates estrogens into their active forms, which are capable of binding to estrogen receptors and
influencing estrogen-dependent physiological processes.
FIGO: International Federation of Gynecology and Obstetrics.
GaP: Genotype and Phenotype Registry (registry of normal/control research subjects).
GnRH: Gonadotrophin releasing hormone.
Growth factor: A substance capable of stimulating cell growth, proliferation, and differentiation.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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Gut-brain axis: Consists of bidirectional neural processing of information between the central nervous
system and digestive system. Recent research indicates that gut microbiota is a crucial part of the gutbrain network and communicates with the brain through the microbiota-gut-brain axis.
HIF: Hypoxia inducible factor.
HMB: Heavy menstrual bleeding.
Hologenome: Theory that maintains that the physiology of any macroscopic organism derives from the
integrated activities of the individual genomes contributing to the organism (holobiont).
LNG-IUS: Levonorgestrel-releasing intrauterine system
ME: Menstrual effluent.
ME-SFCs: Menstrual effluent derived stromal fibroblast cells.
mHealth: Mobile health.
Microbiota and Microbiome: The human microbiota encompasses the group of microorganisms that
live in association with the human body. Conversely, the microbiome refers to the genes and genomes
of this microbiota as well as their products within the host environment.
micro-RNA: Small noncoding RNA molecule regulating posttranscriptional gene expression.
MRI: Magnetic resonance imaging.
MSCs: Mesenchymal stem cells.
MT-MRI: Magnetization transfer-MRI.
Multipotent stem cell: A cell that can self-renew by division and can develop into multiple
differentiated cell types.
Natural killer (NK) cell: A type of lymphocyte that can bind to certain tumor cells and virus-infected
cells without the stimulation of antigens and can kill them by the insertion of granules containing
perforin.
PA: Plasminogen activator.
PAEC: Progesterone receptor-modulator-associated endometrial changes.
PAI: Plasminogen activator inhibitor.
PALM: Polyps, Adenomyosis, Leiomyoma, Malignancy.
Paracrine signaling: Signaling involving hormone that has an effect only in the vicinity of the cell
secreting it.
PCOS: Polycystic ovary syndrome.
Richness (Alpha diversity): Refers to the diversity within a particular area or ecosystem. It is usually
expressed by the number of species (species richness) in a unique niche.
ROSE: Research OutSmarts Endometriosis (research program dedicated to studying endometriosis).
SPRM: Selective progesterone receptor modulator.
TGF-β3: Transforming growth factor-beta 3.
T2W: T-2 weighted.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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t-PA: Tissue plasminogen activator.
uNK cells: Uterine natural killer cells.
u-PA: Urokinase plasminogen activator.
In September 2018, the Gynecologic Health and Disease Branch (GHDB) of the Eunice Kennedy Shriver
National Institute of Child Health and Human Development (NICHD) convened a 2-day meeting to
“identify gaps and opportunities in menstruation science and to raise awareness of the need for more
research in this field.” Leaders in the field with expertise in endometrial biology, omic analysis of the
endometrium and menstrual effluent, new imaging or sampling modalities, smart technologies or
applications (apps) and mobile health (mHealth) platforms, menstrual health, and health literacy and
dissemination frameworks were invited to participate as speakers and discussants to critique and
summarize new discoveries and avenues of future research surrounding menstruation. This meeting
encompassed normal menstrual health and endometrial function and the potential of diagnostics for
abnormal functioning and disease. To provide a broad perspective on menstruation science, this meeting
included investigators and stakeholders across multiple disciplines, including population health and public
health sectors, and carefully considered the broader societal implications of menstrual health. This
manuscript summarizes the presentations and discussions that took place at the 2018 “Menstruation:
Science and Society” meeting hosted by GHDB, NICHD.

1. Toward a Better Understanding of Menstrual Health: Menstrual Health
Literacy and Communication
Kristen A. Matteson, MD, MPH; Missy Lavender, MBA; Erica E. Marsh, MD, MSCI; Kami Silk,
PhD
I. Introduction
According to the World Health Organization, “health” is “a state of complete physical, mental and social
well-being and not merely the absence of disease or infirmity.”1 For women, menstrual health is an
integral part of overall health because, between menarche and menopause, most women menstruate and
menstruation can have a significant impact on the physical, mental, and social well-being.2 Normal
menstruation is currently defined as cyclic bleeding that occurs from the uterine corpus between menarche
and menopause. It can be described in terms of 4 simple domains: how frequently the woman has episodes
of bleeding, the regularity or predictability of these episodes, the duration of bleeding episodes, and the
volume or heaviness of bleeding.3, 4, 5 Not all women experience “normal” menstrual bleeding; up to 30%
of women will experience alterations in the volume or pattern of menstrual blood flow, which is defined as
the symptom of abnormal uterine bleeding (AUB), which in turn can be caused by multiple etiologies and
sometimes more than 1 etiology at the same time.3,6 In addition, many women will have other symptoms
such as pain, dysmenorrhea, anxiety, depression, and fatigue associated with their menstrual cycle that
require attention for them to achieve early diagnosis of reproductive health issues such as endometriosis,
premenstrual syndrome, and premenstrual dysphoric disorder and attain optimal health. In research and in
clinical care, a better understanding of what the norms of menstrual health are and how a “lack” of
menstrual health affects women’s quality of life is needed. Furthermore, for positive health and well-being
outcomes, everyone—men and women, as well as clinicians—need to understand menstrual cycles and
menstrual health, which can be achieved through menstrual health literacy initiatives and improved health
communication.
Menstrual health and menstrual health literacy are extremely broad topics with multiple stakeholders and
diverse areas of active investigation and contributors. Adapted from the broader health literacy definition,
menstrual health literacy refers to the level of capacity a person has to obtain, process, and understand
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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basic information about menstruation so they can make appropriate health decisions.7 This section of the
manuscript summarizes the presentations and discussion that took place related to menstrual health and
menstrual health literacy at the 2018 “Menstruation: Science and Society” meeting hosted by the GHDB of
the NICHD. We summarize only areas of menstrual health and literacy that were part of the presentations
and active discussions at the NICHD GHDB meeting, which were largely focused on the bleeding aspect
of menstrual health.
II. Progress in menstrual health terminology and menstrual health literacy and
communication
Progress in menstrual health terminology Standard terminologies related to menstrual bleeding, and

specifically AUB, represent real progress for clinical care and research. Ill-defined terminologies to
describe symptoms, signs, and diagnoses associated with AUB led to communication challenges in clinical
care, difficulty interpreting populations included in published literature, and lost opportunities for multisite
research collaboration for clinical research on treatments for AUB.
In 2005, the Menstrual Disorders Working Group of the International Federation of Gynecology and
Obstetrics (FIGO) embarked on a worldwide consensus-building process to generate and disseminate a
simple symptom description system and a classification system for the etiologies associated with AUB.8,9
The first system, “Terminologies and Definitions,” includes standard definitions for bleeding symptoms
domains, which include regularity, frequency, duration, and volume.3 The second system, “Classification
of Causes of AUB in the Reproductive Years,” commonly referred to as the
polyps/adenomyosis/leiomyoma/malignancy (PALM)–coagulopathy/ovulatory/endometrial/iatrogenic/not
otherwise classified (COEIN) system, includes a list of etiologies that can be associated with AUB
(polyps, adenomyosis, leiomyoma, malignancy and hyperplasia, coagulopathy, ovulatory, endometrial,
iatrogenic, and not otherwise classified). Results of this work were published in peer-reviewed
publications and were used by the American College of Obstetricians and Gynecologists (ACOG) during
their process standardizing terminologies used across gynecologic specialties.4,5 ACOG and the members
of the Women’s Health Registry alliance convened the revitalize Gynecology Data Definitions initiative in
December 2013 to develop standardized data elements and definitions in gynecology. Throughout this
process, ACOG engaged a broad range of stakeholders to identify priority topics and definitions and then
worked with a core group of contributors to generate a total of 119 data elements, including 7 pain-related
and 7 bleeding-related definitions.4,5 Although there is more work to be done in terms of evaluating these
definitions across diverse populations of women, these standardized terminologies represent positive first
steps to facilitate research data collection, collaboration for study participant recruitment, and
identification of study cohorts with similar etiologies when investigating the prevalent symptom of AUB.
Another area of progress has been increased emphasis on the patient experience of bleeding, quality of life,
and related symptoms associated with the menstrual cycle in both research and national guidelines. The
National Institute for Health and Clinical Excellence (NICE) Clinical Guidelines on Heavy Menstrual
Bleeding (HMB) published a patient-centric definition of the symptom of HMB, which they define as
“excessive menstrual blood loss that interferes with a woman’s physical, social, emotional, and/or material
quality of life.”10 Qualitative and quantitative research with women to learn about their experiences with
and knowledge of menstrual bleeding, fibroid-related symptoms, pain, and other associated symptoms has
begun to inform research priorities, educational tools, and the need for outcome measures for AUB and
uterine fibroids.11, 12, 13, 14 Several studies have suggested that patient-reported outcome measures
(PROMs), which include standardized interviews, questionnaires, charts, and surveys that assess the
patient’s own evaluation of her health and symptoms, are the key to assessing the impact of illness and
symptomatology among women with reproductive health issues including AUB.2,15, 16, 17, 18, 19
Progress in menstrual health literacy and communication
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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There has been recent progress in the areas of menstrual health literacy, advocacy, and communication, in
part facilitated by the rapid acceptance of mHealth apps, the use of mobile technologies to provide healthrelated services (tracking information and providing information or education to support an individual’s
achievement of health objectives).20,21 At present, there are more than 300 reproductive health mHealth
products in the IOS and Google stores, with the majority of the apps focused on women of childbearing
age. The apps vary in their depth of pelvic health information, with the majority including cycle and
fertility trackers. Two of the larger apps as far as global reach, CLUE and FLO, have expanded both their
tracking (CLUE) or daily notifications and information (FLO) to include facts or daily tips, which, though
brief, may be useful to assist in identifying women with the symptom of AUB. Additional data are needed
to better understand the demographics of and reasons why women use these apps.
III. Significant conceptual, practical, or technical challenges in the field of menstrual
health research and menstrual health literacy
The progress in the field of menstrual health outlined previously is remarkable given the multiple
challenges and obstacles in the field of menstruation science. Menstruation is a physiological process that
is experienced almost universally across cultures from the ages of menarche to menopause. What makes
menstrual health and menstrual health literacy challenging to study is that for many, it is a normal process
that is not associated with any distress or disability, but for some it can be associated with a significantly
negative impact on the quality of life. Collecting data on a nearly universal process will require
collaboration across the spectrum of disciplines and careful consideration of “who” to collect data from,
“what” data elements to collect, and “how” to best collect data. Furthermore, the normalization of
women’s pain and stigma surrounding menstrual bleeding and reproductive health represent significant
barriers to women’s care seeking, diagnosis, and ability to conduct research in this area.22 Menstrual
health and menstrual health literacy research is further complicated by a lack of standardization of tools
and access to those tools, the multiple different etiologies of HMB, the multidimensional symptom
complex surrounding bleeding, lack of clear diagnostic tests for reproductive health disorders that affect
menstrual health, suboptimal norms for menstrual health and bleeding across the life span, and insufficient
information related to cultural perceptions related to menstrual bleeding and health.
Although awareness of the importance of patient experience with menstrual bleeding and menstrual
symptoms has increased in research and clinical care, sustained reliance on “objective” laboratory
measures for outcomes related to menstrual health represents an additional conceptual barrier to progress
in this area. To provide an AUB-specific example, traditionally in research, bleeding was measured by
volume of menstrual blood lost (>80 mL) as measured by the collection of used sanitary products and
quantified using the alkaline hematin method.23 However, research has highlighted that most women who
seek treatment for HMB do not meet the objective mean blood loss criteria for heavy bleeding and clinical
care objectively measured blood loss is not feasible.19 As a result of these studies and others, NICE, the
National Health Services (NHS) in the United Kingdom, stated in 2018 that “From the woman’s point of
view objective reduction in mean blood loss are poor indicators of treatment effectiveness for heavy
menstrual bleeding.”10 This lack of consistency between what has been prioritized as a measurement for
research and what women prioritize in terms of desired outcomes represents a current obstacle for highquality research and synergy between research on HMB, clinical care, and patient-centered care delivery.
IV. Critical gaps in menstrual health literacy, advocacy, or communication and how they
can be addressed to optimize women’s menstrual health
Conceptual, practical, and technical challenges related to research on menstrual health and menstrual
health literacy and communication have led to several critical gaps in the evidence base in this area.
During the meeting, several gaps in the evidence base and opportunities to improve women’s health by
addressing these gaps with high-quality research were discussed.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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Data to inform “norms” that hold across populations and span from menarche to menopause Gener

ation of standard terminologies related to norms for uterine bleeding among adult women represents
significant progress in the field of menstrual health, and there has been significant progress especially in
describing symptom expectations in the later reproductive life stages and during the menopausal
transition.24, 25, 26, 27 To ensure that menstrual bleeding norms represent bleeding patterns and other
menstrual health symptoms across a racially and ethnically diverse and contemporary population (relative
to comorbid conditions and body mass index) of women of all ages, further research is needed.28
Prospective longitudinal cohort data on menstrual bleeding, menstrual symptoms, and reproductive health
diagnoses could fill this critical gap.
Developments in mHealth could also be used to inform norms and measure the personal impact
menstruation and menstrual symptoms have on women across the life cycle. For population-based data
outside of clinical care, data collected from mHealth and mobile device apps are starting to enable the
analyses of population-level longitudinal menstrual symptom and cycle data.29 In addition, these mHealth
data could facilitate investigation into cultural differences, knowledge, attitudes, and behaviors. By
partnering with mHealth and app platforms, researchers, clinicians, and industry could generate data
collection mechanisms and assist in generating research programs and interventions that could aid women
in identifying when they are having a problem and address stigma and perceptions related to menstrual
disorders, delays in diagnosis of reproductive health disorders, and delays in care seeking.
Standardizing data collection in research, clinical care, and mobile health technologies to promote
consistency and optimize comparative effectiveness research

A shift in research to focus on measuring patient experiences with symptoms and chronic health problems,
including reproductive health and menstrual health issues, represents significant progress in the arena of
women’s health. However, although there are several validated PROMs for AUB, there is no single highquality PROM that is considered “standard of care” or “standard for use across studies.”17,30,31 This
translates into hundreds of outcome measures, of varying quality, used across studies and an inability to
combine data across studies to summarize patient experience. In a systematic review of patient-reported
outcomes used across studies of AUB, authors found 80 studies that used at least 1 PROM and 77 different
PROMs were used across studies.31 The Society of Gynecologic Surgeons, in a systematic review
comparing treatments for HMB, identified that 114 different outcomes were collected and reported across
79 distinct clinical trials.17 The end result was that, because the method of assessing outcomes differed
from study to study, data could not be combined or summarized for these outcomes (such as quality of life
and bleeding-related quality of life), which prohibited the group from generating consensus on treatment
effectiveness relative to patient-reported outcomes.17 Researchers across disciplines of menstrual health
research have expressed challenges describing the menstrual symptom phenotype of patients involved in
clinical research because of a lack of standardized structured menstrual history data elements. Finally,
discussions at this meeting also highlighted the importance of a broader view of menstrual health that goes
beyond bleeding to include other associated symptoms, which will need additional research and
standardized data elements.
The research community can collaborate to address this challenge and standardize outcomes and data
elements for research and quality assessments. For example, the Core Outcomes in Women’s and Newborn
Health, an international initiative led by journal editors and is endorsed by more than 80 peer-reviewed
journals in women’s health, is working to stimulate the development of outcome sets that can be used
across studies to ensure consistent outcome reporting, thereby improving the interpretability of study
results and the feasibility of combining data across studies.32,33 Efforts to standardize data elements from a
structured menstrual history describing frequency, regularity, duration, and patient-quantified volume of
bleeding along with other associated menstrual symptoms are needed to facilitate consistent descriptions of
populations in studies on menstrual health, AUB, uterine fibroids, and other reproductive health issues.34
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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V. Additional future directions in menstrual health research
Transforming comparative effectiveness research by incorporating patient-reported outcome
measures into electronic health records

Looking to the future, standardizing and harnessing the potential of patient-based outcomes assessment
could transform comparative effectiveness research. Emerging technology developments may be paving
the way to have PROM collection integrated into electronic health records, which would promote patientcentered comparative effectiveness research.35,36 Researchers, policy makers, and professional societies
are currently working out best practices for integrating PROMs and electronic health records.35,36 This
integration could mean substantially greater capabilities for patient-relevant comparative effectiveness
research and health services research, which often relies on electronic health record or administrative
datasets that rarely incorporated patient-reported data elements, particularly on reproductive health
problems that affect the quality of life.
Incorporating PROM collection into clinical care encounters may represent major opportunities to evaluate
processes of healthcare delivery. Future research opportunities include assessing whether or not
incorporating PROMs into electronic health records and clinical encounters for menstrual health disorders
can improve physician-patient interactions and be used to monitor patient symptoms or progress over time.
On the population level, incorporating PROMs into clinical care can assist with clinical care quality
assessment and population surveillance. For example, in the UK NHS, PROMs are collected before and
after certain surgical interventions to determine the quality of care delivery and to facilitate counseling for
patients on what to anticipate in terms of the personal impact of the surgery.37
Partnerships across diverse disciplines and stakeholder groups Innovative solutions to address

comprehensive menstrual health across the life span will require collaboration across scientific disciplines,
social science disciplines, and involvement of patient- and person-facing organization to ensure the
relevance and success of these solutions for addressing the needs of the population. Menstrual health
research in the future could be enhanced by developing collaborative interdisciplinary teams to investigate
comprehensive menstrual health premenarche to menopause. In addition, including patient-facing groups
in study design and beta testing of programs from the beginning and partnering with patient groups and
advocacy groups to create and disseminate communication platforms and menstrual health educational
initiatives could enhance the fields of menstrual health, menstrual health literacy, and menstrual health
communication.
VI. Conclusion
Each year, 4.5 million women in the United States experience at least 1 gynecologic health problem, and
many of these problems are related to menstrual health.6 Although significant progress has been made in
menstrual health research in terms of emphasizing patient experience, standardizing terminologies related
to menstrual bleeding, and use of PROMs for menstrual disorders, more work and research are needed to
standardize data collection, generate longitudinal data on contemporary norms of menstrual bleeding and
related symptoms, and optimize use of new technologies and educational interventions. Health
communication strategies that are accessible to groups with low literacy and address potential stigma
associated with menstruation will help to address barriers as well. Increasing the evidence base on
menstrual health and menstrual health literacy will aid in the evolution of contemporary clinical care that
meets the unique needs of women. Bringing women and advocacy groups to the table and bringing data
collection and information directly to women through innovative technologies, smartphone apps, and
mHealth has the potential to move the field of menstruation science away from treating problems and
toward optimizing women’s overall health, and more specifically menstrual health. Continuing the recent
momentum on patient-focused menstrual health research to sustain progress in the field of menstrual
health, literacy, and communication has the potential to have a substantial impact on the lives of women.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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2. The Evolutionary History of Menstruation
Günter P. Wagner, PhD
Menstruation and its associated diseases such as HMB and AUB are a significant burden on women of
reproductive age (see section Menstruation and abnormal uterine bleeding below), which raises the
question of why women menstruate at all. This question is particularly pertinent given the fact that
menstruation is dispensable for mammalian reproduction (see below). Answers require a review of the
evolutionary history of mammalian reproduction, given that humans and great apes, that is, species that
menstruate, evolved from ancestors that did not menstruate. What are the advantages menstruation affords
humans and other primates that, from a biological point of view, could make the origin and biological role
of menstruation understandable?
I. Menstruation is rare among animals
Menstruation is defined as the shedding of the upper (the so-called “functionalis”) layer of the uterine
lining after the luteal phase of the ovarian cycle. Although menstruation is a normal part of the life of a
woman during her fertile years, it is only found in a small minority of animals. Because menstruation is a
function of the female reproductive organs, one would expect to find menstruation in animals with a
similar mode of reproduction as humans, that is, the so-called placental mammals (technically called
“eutherian mammals”). Eutherian mammals are all the species that descended from the most recent
common ancestor of humans and elephants, meaning all the mammals that we are most familiar with: apes,
monkeys, farm animals, cats, dogs, seals, hedgehogs, and others (Figure 2). All of these animals have a
placenta and a gestational period that is longer than their ovarian cycle, so-called trans-cyclic gestation,38
with the exception of animals that have pseudopregnancy in the absence of fertilization, such as the dog.39
Despite the substantial similarities, with respect to female reproductive biology, between humans and all
other eutherian mammals (eg, compared with reptiles and birds), menstruation only occurs in a small
minority of eutherian species. The largest cluster of menstruating species is found among our closest
relatives, the primates. In particular, apes, old world monkeys, and most but not all of new world monkeys
have menstruation. More basally diverging primate lineages do not (lemurs and tarsiers, where in the latter
conflicting evidence has been reported, summarized in the study by Emera et al40). Outside the primates,
menstruating species are rare. Among the rodents, only one species has been described as menstruating:
the spiny mouse, Acomys cahirinus.41 This is surprising, given the large number of rodent species (2277
species). Then there is a small number of bat species belonging to 2 groups of bats, 1 molossid bats and 3
phyllostomid bats.42 Most distantly related menstruating species to humans is the elephant shrew
(Elephantulus myurus43,44) related to elephants and other afrotherian mammals. These menstruating
species add up to 84 species, or about 1.6% of the 5149 recognized extant eutherian species. This estimate
could be a slight undercount because it is not easy to diagnose menstruation in species that have not been
kept in laboratories or zoos and have been closely monitored.
If we put the menstruating species on the phylogeny of mammals (Figure 2), we see a rather dispersed
distribution. Clearly, all the primate species that menstruate are relatively closely related, but the spiny
mouse, bats, and the elephant shrew are not. The conclusion that follows from these facts is that
menstruation must have evolved at least 4 times independently during the evolutionary history of
mammals. This conclusion is also supported, for instance, by differences in the exact location and nature
of the endometrial changes in the elephant shrew (summarized in the study by Carter45). The rarity and
repeated evolution of menstruation raise the question about its biological role. Menstruation is clearly not
necessary for a mammal because it is rare, but it might have a specific role, rather being there accidentally,
because it originated at least 4 times independently.
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Before we turn our attention to the question of why some mammals menstruate and others do not, we
should mention that not every case of vaginal bleeding by a healthy animal is menstruation. The best
known example is the vaginal bleeding of the dog, which is not a sign of menstruation.39 The main
difference between what is happening in dogs and in menstruating species is that the vaginal bleeding in
dogs happens in proestrus, that is, in preparation for mating, rather than after the fertile phase is over, as it
is the case in women. The bleeding in dogs is caused by extravasation during the growth of the uterine
lining, which can break through the epithelium leading to a vaginal efflux.
II. Why did menstruation evolve?
The fact that menstruation plays a major role in the life of a woman and that it is rare among animals has
inspired many scientists, anthropologists, and medical researchers to speculate about its biological role.46,
47, 48, 49, 50, 51, 52
This is not the place to review all the ideas that have been proposed to explain the
evolution of menstruation but note that the most honest and shortest answer to this question is “we do not
know.”53 Nevertheless, there has been some progress in reframing the question that points to two plausible
answers.
An important breakthrough in understanding the evolution of menstruation was the realization that
menstruation itself may not be the direct biological trait that was shaped by natural selection, but rather
that menstruation could be a secondary consequence of an underlying biological trait: spontaneous
decidualization.52
Decidualization is the process by which the uterine lining prepares for pregnancy. This is a complex
process including proliferation of the endometrial stroma, the traffic of various kinds of white blood cells
into the endometrium, and the differentiation of the endometrial fibroblasts into so-called decidual stromal
cells (DSCs).54 Decidualization in the narrow sense refers to the differentiation of DSC, rather than to the
whole organ-level process. In most animals, decidualization occurs in the estrogen- and progesteroneprimed uterus in response to the presence of the embryo. This is induced decidualization. However, in
humans, decidualization occurs even in the absence of an embryo and is therefore called spontaneous
decidualization. It turns out that all menstruating species undergo spontaneous decidualization,40,41,52
suggesting that the evolved trait is not menstruation per se, but spontaneous decidualization. In humans, it
has been shown that the proximate cause for menstruation (see section on Menstruation and abnormal
uterine bleeding) is the decrease in progesterone levels owing to the degeneration of the corpus luteum. An
experimental model of artificial decidualization in a nonmenstruating species, the mouse, Mus musculus,
shows that in fact progesterone withdrawal after decidualization is sufficient to cause menstruation-like
symptoms, that is, degeneration of part of the endometrium and vaginal bleeding.55, 56, 57, 58
There are several versions of this experiment but the cleanest model is the one published by Rudolph
et al56 in 2012: intact female mice were mated with sterile, vasectomized males, which in mice causes
pseudopregnancy, meaning that the female maintains a high level of progesterone even though no fetus is
developing in her uterus. After copulation, the pseudopregnant mice were injected with a small droplet of
oil into the lumen of the uterus. It is known that this treatment causes the uterine lining of the mouse to
decidualize, leading to a so-called “deciduoma,” which is a condition that, in many respects, mimics fetusinduced decidualization. The key observation of this experiment then was that as progesterone levels were
decreasing toward the end of the pseudopregnancy, menstruation ensued. This result supports a model
according to which menstruation is an inevitable consequence of spontaneous decidualization if
fertilization and pregnancy do not occur (Figure 3).
Both, the comparative evidence, namely, the association between menstruation and spontaneous
decidualization among mammals, and the experimental evidence with artificial decidualization lead to the
conclusion that the real question thus is not “why some species menstruate?” but “why do some species
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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show spontaneous decidualization and menstruate as a consequence?” There are 2 plausible answers, but
no definite consensus on this issue has been reached.
One model assumes that spontaneous decidualization is a protective device for the mother against an
aggressive fetus.40,47,52 This model is based on the observation that the degree of invasiveness of the
placenta varies between species. This is even the case among species with so-called hemochorial
placentation, that is, where the fetus is destroying not only the uterine luminal epithelium but also some of
the uterine blood vessels so that the placenta is in direct contact with maternal blood. For instance, great
apes have extravillous trophoblast cells, which invade the maternal blood vessels (spiral arterioles), the
stroma, and even the muscular layer of the uterus (myometrium).59 Clinical observations have also
revealed cases where a placenta embeds too deeply into the uterus, a condition called “placenta accreta” or
“placenta percreta” depending on the depth of invasion. These conditions can threaten the life of the
mother after birth because of massive uterine bleeding.60 Finally, one of the roles of the decidual cells is to
both enable and limit the invasion of the placenta and thus regulate the depth of implantation even though
the mechanisms are still unclear. Hence, it seems plausible that spontaneous decidualization is ensuring
that a conceptus finds an environment that is prepared to allow and at the same time limit the degree of
placental invasion. To our knowledge, no formal test of this model has been attempted. In particular, one
would need a way to measure invasiveness of the conceptus in various animals, many of which are not
laboratory models and thus hard to work with. Furthermore, we have no information whether and which
close relatives of menstruating species are also menstruating to test for a correlation between menstruation
and depth of placental invasion.
The second model to explain the evolutionary origin of menstruation assumes that spontaneous
decidualization is an adaptation to allow the female to “test” the viability of the conceptus before definite
pregnancy ensues.61, 62, 63, 64 This model is inspired by the observation that decidual cells have the ability
to sense the vitality of the embryo and react with a stress reaction when the embryo is of inferior quality.
The idea is that this ability of DSCs helps the mother avoid investing resources in an ultimately
unsuccessful pregnancy and thus increases the reproductive fitness of the female by allowing her to
achieve pregnancy sooner. This idea is supported by the fact that humans have a rate of pregnancy loss of
10% to 25%65 (higher estimates found in the literature seem to be spurious) and that spontaneous
decidualization is primarily found in animals with a small litter size, that is, one or two neonates per
pregnancy and thus with correspondingly higher investment into each offspring. The recently described,
yet not fully evaluated, spiny mouse is somewhat an exception because its litter size is usually 2 or 3 but
can be as high as 6.41 Again, there is a dearth of comparative data to fully test this idea, given that we do
not know the rate of pregnancy loss in most animals, and whether it is different between closely related
species that differ in the presence or absence of spontaneous decidualization.
III. An evolutionary argument for the validity of menstruation as a diagnostic tool
In a later section, the utility of menstrual efflux as a diagnostic tool will be discussed in detail. Here, we
review an evolutionary argument that supports the idea that menstruation may be predictive of pregnancy
complications in the future.
In the evolution of spontaneous decidualization, the decidualization process becomes independent of the
actual initiation of pregnancy. Nevertheless, it is uncontroversial that the process of spontaneous
decidualization is homologous to the process of embryo-induced decidualization as the former evolved
from the latter.40 The only difference is the mode in which the decidualization is triggered, either by
maternal hormones as in spontaneous decidualization (as in women) or by the embryo as in induced
decidualization (as in the mice or rodents). This is the reason why experimental work on mice is a valid
approach toward understanding human decidualization even though the mode of decidualization is
different between these two species.
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC7661839/?report=printable
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At the end of the ovarian cycle, menstruation is caused by the withdrawal of the supportive function of
progesterone for the decidua. As a consequence, menstruation has substantial mechanistic similarities with
the processes that initiate labor.66 Birth is also associated either with a systemic progesterone withdrawal
through the degeneration of the corpus luteum (luteolysis) or by functional progesterone withdrawal
caused by inhibition of progesterone signaling.67,68 Hence, it is likely that the mechanisms deployed in the
uterus during menstruation are homologous to those during parturition.66 If in fact menstruation and the
uterine manifestations of parturition are homologous, it is likely that defects that affect the maintenance
pregnancy or the initiation of parturition could also manifest themselves as aberrations in menstruation.
Pavlicev and Norwitz66 therefore suggest that substantial research effort should be dedicated toward
testing whether biomarkers expressed during menstruation are associated with pregnancy complications
that could be useful as preconception diagnosis of likely pregnancy complications.

3. Menstruation in Humans
3A. Menstruation and abnormal uterine bleeding
Hilary O.D. Critchley, MD; Jacqueline A. Maybin, PhD
I. The impact of menstrual bleeding complaints Understanding the mechanisms underpinning the pivotal

human event of menstruation is critical to our understanding of AUB. AUB, which includes the symptom
of HMB,3 is a chronic complaint that affects the quality of life and well-being of 1 in 4 women of
reproductive age (Figure 4).69 Previously, women experienced menstruation approximately 40 times
owing to pregnancy and lactation amenorrhea, whereas in developed economies today, women can expect
up to 400 menses in their lifetime.70 Therefore, AUB is becoming more common and problematic for
women and society. In contemporary society, women are delaying having children for a variety of reasons
such as personal choice, prioritization of career, and other factors that impose a delay in childbearing.
Therefore, these women wish to preserve their uterus alongside their fertility. As a consequence, surgical
options are not always appropriate because these end fertility and may also involve higher risks than
medical management alternatives. In a recent systematic review relevant to the United States, it was
conservatively estimated that annual direct and indirect economic costs of menstrual bleeding complaints
were in the order of $1 billion and $12 billion, respectively.71 Leiomyoma (uterine fibroids) are common,
present in 70% to 80% of women by the age of 50 years,72 and associated with AUB or HMB. Among
women in their 30s and 40s, leiomyomas are often the underlying cause of AUB, anemia, and iron
deficiency anemia. When the presence of uterine fibroids is considered along with complaints of AUB, the
annual estimated direct costs of this complaint in the United States, when surgery, hospital attendances,
outpatient visits, and prescribed medications are taken into account, are as high as $4.1 billion to $9.4
billion. Furthermore, lost work hours resulted in costs ranging from $1.55 billion to $17.2 billion.71
II. A classification system for abnormal uterine bleeding To provide diagnostic precision and specific

treatment of AUB, classification of causes of uterine bleeding is crucial. The FIGO Menstrual Disorders
Committee has led on the classification systems for causes of chronic AUB in the reproductive years.3,73
As already mentioned, there are 2 systems: the first system focuses on terminology with an encouragement
for the removal of ill-defined terminologies such as “menorrhagia” and “dysfunctional uterine bleeding,”
and the second system focuses on the underlying causes of AUB, using the acronym PALM-COEIN3,73
for structural and nonstructural causes, respectively (Figure 5). It is hoped that these 2 FIGO systems will
be used globally to improve the management of women with AUB.
In the absence of any other features, for example, leiomyoma or a coagulopathy,3 bleeding from the
endometrium may represent a “primary endometrial disorder” (AUB-E). In the presence of structural
features such as leiomyoma, polyp, and adenomyosis,3 it is not known whether the presence of myometrial
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structural entities such as AUB-L (leiomyoma) or AUB-A (adenomyosis) actually result in a “secondary
endometrial disorder” (Figure 6). There remains a true lack of knowledge about the phenotype of the
endometrium when adenomyosis and leiomyomas are present.
This exciting area merits substantial research and many questions remain. What is the aberration in women
with AUB-E? Do leiomyomas and adenomyosis contribute to the genesis of AUB or HMB? If so, is it
because they directly affect the molecular mechanisms of endometrial hemostasis? Do leiomyomas
actually need to be adjacent to the endometrium to cause AUB?74 To answer these important questions, we
need to fully understand endometrial physiology and pathology.
III. Methods for the study of menstruation Identification of aberrations in endometrial function

necessitates study of human endometrial tissue. Women must have a detailed clinical history and
examination and undergo investigation to determine if structural disorders are present. For research
purposes, women should have measurement of their menstrual blood loss to enable categorization as
having heavy or normal menstrual bleeding. An objective measurement of blood loss may be obtained
using the alkaline hematin method and total menstrual volume by using a menstrual cup.23,75
Alternatively, a pictorial menstrual blood loss assessment chart has been validated to assess menstrual
blood loss volume and duration.76 In addition, tissue must be carefully classified to determine the correct
stage of the menstrual cycle.
Studies in women are often limited to generation of observational data. For more incisive functional
studies, animal models of simulated menstruation have been developed.55,77, 78, 79 The nonhuman primate
(rhesus macaque) has been studied extensively and provides an excellent model of the human menstrual
cycle.80,81 More recently, attention has focused on refinement of the mouse model of simulated
menstruation.55,57,77,79
A detailed study of the cellular and histologic events occurring in the mouse endometrium during
simulated menstruation has been reported to recapitulate several of the local events that occur in the human
endometrium at the time of menstruation, these being apoptosis preceding cytokine and chemokine
expression and extensive neutrophil influx into the endometrium.82 There is an interesting recent
discovery of a previously unrecognized menstruating rodent, the spiny mouse, which may provide another
tool in the study of menstruation.41
The combination of observational data generated from well-categorized human endometrial tissue and
mechanistic studies in validated animal models will facilitate definitive experiments to determine
menstrual physiology and pathology.
IV. Initiation of menstruation The human endometrium is a highly dynamic multicellular structure. Its

physiological functions are preparation for implantation and, in the absence of pregnancy, menstruation.
The regulation of normal menstruation is governed by sequential exposure to circulating sex steroids,
estrogen, and then estrogen and progesterone followed by corpus luteum demise causing a fall in both
circulating estrogen and progesterone. Progesterone withdrawal is the trigger for menstruation.53,83
Menstruation involves a remarkable sequence of endometrial cell proliferation, differentiation, shedding,
and regeneration that may occur as many as 400 times across the reproductive life course.70 The
mechanisms underpinning menstruation still remain poorly understood. There are crucial interactions
between the endocrine system and the immune system.53,83 These cellular interactions, which are
dependent on the menstrual cycle phase, involve epithelial and stromal cells along with an influx of innate
immune cells and differentiation of the endometrial vasculature (spiral arterioles). The local endometrial
events at the time of menses resemble those of an inflammatory event. There is an increase in endometrial
blood vessel permeability and fragility, tissue breakdown, and an influx of innate immune cells into the
endometrium, particularly neutrophils and macrophages.82,84,85
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V. Cessation of menstruation The cessation of menstrual bleeding and endometrial repair require 3

closely related events: these being vasoconstriction of the highly specialized spiral arterioles, local
endometrial hemostasis, and reepithelialization of the injured endometrial mucosa (Figure 6). After
menstruation, the restoration of the injured mucosal surface is a rapid event and the role of endometrial
stem cells is addressed in the following contribution concerning endometrial regeneration. Endometrial
repair of the denuded epithelial surface after menstruation has been described by Garry et al,86 using
hysteroscopy, histology, and scanning electron microscopy. These imaging techniques detail the temporal
repair of the epithelial surface, which occurs in a piecemeal fashion adjacent to actively menstruating
tissue.86 The regulation of this endometrial repair process is not fully defined. There is a recent interesting
interpretation of the link between human menstruation and separation of the placenta after delivery. Both
are underpinned by progesterone withdrawal and critically involve uterine spiral arterial function.87
In women with complaints of HMB, impaired vascular differentiation caused by impaired spiral arteriole
maturation has been described88, 89, 90 along with exposure to an imbalance of locally generated
vasoconstrictors and vasodilators.91, 92, 93 An increase in blood vessel radius will affect the resistance to
blood flow (Poiseuille’s equation).91 The pivotal role for vasoconstriction after progesterone withdrawal
was described nearly 80 years ago.94 The study of autologous transplants of rhesus macaque endometrium
into the anterior chamber of the eye and visualization of the events of menstruation through a slit-lamp
ophthalmoscope revealed transient and intense vasoconstriction 4 to 24 hours before menstruation in
response to steroid withdrawal. Authors proposed that this vasoconstriction was consistent with local
tissue hypoxia. The presence and role of endometrial hypoxia in the process of menstruation have been
debated. There is now experimental support for a pivotal role for transient physiological hypoxia because
it has been reported to occur in the menstruating endometrium.58 The stabilization of hypoxia-inducible
factor 1 (HIF-1; a marker for hypoxia) results in the generation of local repair factors to “heal” the injured
mucosal surface (menstruating endometrium).58
Women with HMB have decreased endometrial HIF-1α at the time of menstruation, and these women also
experience prolonged menstrual bleeding episodes. These observational data have been recapitulated in a
mouse model of simulated menstruation in which physiological endometrial hypoxia is also reported to
occur at the time of endometrial bleeding.58
Fibrinolysis is an important component of regulation of normal endometrial bleeding. The human
endometrium contains tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA),
along with plasminogen activator inhibitor (PAI) (inhibits fibrinolytic activity) and the u-PA receptor.
Women complaining of HMB have raised levels of t-PA activity on the second day of bleeding when
compared with those with normal menstrual blood loss, consistent with an overactive fibrinolytic
system.95,96 Tranexamic acid, a popular nonhormonal treatment for HMB in many countries, targets the
overactivation of the fibrinolytic system with a reported 58% reduction in menstrual blood loss.97
VI. Endometrial pathology in structural abnormal uterine bleeding In the presence of structural

pathologies (AUB-P/A/L), a secondary endometrial disorder has been proposed (Figure 6). The current
literature presents lines of evidence to support the concept that there may be an element of resistance to
normal progesterone-regulated events.98,99 The latter is based on descriptive data and may certainly be
implicated given the often reported poor response to many progestin-based therapies, for example, the
levonorgestrel-releasing intrauterine system and oral, implant, or injectable progestins.69
VII. Therapies targeting the progesterone receptor Progestins have long been used to modulate

endometrial bleeding either through their action on ovarian function or abolition of ovulation along with a
direct effect on the endometrium to reduce bleeding. All progestins, when delivered orally, systemically, or
through an intrauterine route, improve menstrual experience in many women; however, there remains a
consistent 20% who experience unscheduled endometrial bleeding and spotting. This is often a reason for
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the discontinuation of use of progestin therapies. The mechanisms underpinning this unscheduled bleeding
still remain elusive despite studies focusing on many candidate pathways.100, 101, 102, 103, 104 To date,
there has been no reliable preventative intervention, albeit there are strategies to stop or reduce a heavy
bleeding episode in users of progestin-only preparations.105
Selective progesterone receptor modulators (SPRMs) reduced endometrial bleeding in women with uterine
leiomyomas.106,107 SPRMs inhibit ovulation in 90% of women and also affect the endometrium and many
women experience amenorrhea.108 The mechanisms of action of SPRMs on the endometrium in women
with abnormal bleeding and uterine leiomyoma still remain poorly understood. SPRMs have an interesting
antiproliferative effect, and the study of cell-to-cell interactions within the endometrium in women
exposed to this class of drug is a current topic of investigation.109 SPRM administration is associated with
an unusual morphologic effect on the endometrium known as progesterone receptor–associated
endometrial changes (PAECs). These morphologic features are associated with alterations in expression
and localization of sex steroid receptors.109, 110, 111, 112 The fact that circulating estradiol levels remain
consistently in midfollicular range has raised concerns among clinicians about the risks of hyperplasia and
endometrial cancer. However, no studies to date that have explored in detail the endometrial impact have
reported increases in either hyperplasia or endometrial cancer.113,114 Moreover, a recent systematic review
reporting the endometrial effects of SPRM (ulipristal acetate [UPA]) use in 10 studies involving 1450
women supports the current view that PAEC is essentially a benign endometrial morphology that is
reversible on discontinuation of UPA use.115
VIII. Summary comment Understanding the pathology underlying AUB is essential to improve treatments

for this common symptom that has a significant negative impact on women and society. Progesterone and
progesterone receptor interactions play essential roles in uterine physiology and reproduction.
Progesterone withdrawal remains the major trigger for the onset of endometrial bleeding. Menstruation
itself involves repeated episodes of physiological “injury and repair” and a detailed knowledge of
endometrial function is essential for understanding how disturbances in the endometrial function play a
role in AUB. A particular gap is the understanding of endometrial function in women with myometrial
structural features such as leiomyoma and adenomyosis and whether this represents a “primary or
secondary endometrial disorder.” There is without doubt utility and validity of mouse models of simulated
menstruation, particularly when used alongside human studies. Ligands for the progesterone receptor, that
is, progestins and SPRMs, may reduce endometrial bleeding and modulate endometrial form and function.
Identification of novel targets for the treatment of AUB is vital to address the significant personal and
societal burden of this common disorder.
3B. Regeneration after menstruation—the role of stem cells
Hugh S. Taylor, MD
I. Introduction In each monthly menstrual cycle, the endometrium is renewed from the basalis layer.116, 117,
118

This regenerative process recapitulates some features of development and includes production of all
components of the endometrium, including glands, stroma, vasculature, and an influx of immune cells. The
ability to rapidly and repetitively regenerate this tissue is fundamental to reproduction. Therefore, it is not
surprising that there exists a population of cells that serve to replace and maintain the endometrium despite
repetitive loss with menstruation.116, 117, 118 These stem cells maintain a reservoir of regenerative cells
while simultaneously giving rise to more differentiated cells.
II. Endometrial stem cells Early research in stem cells centered on the hematopoietic system, because

experimental transplants to repopulate bone marrow could be performed using tissue ablation.119 These
studies gave rise to the concept that stem cells divide asymmetrically, reproducing the stem cell and giving
rise to a more differentiated cell, in contrast to the symmetrical division observed in somatic cells.119
However, translation of this asymmetrical division concept to other tissues and organs has recently become
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controversial because tremendous plasticity in the fate of epithelial cells in the intestine, liver, and other
organs is being uncovered.119 Although specific mechanisms remain debated, stem cells throughout the
body maintain the pool of regenerative stem cells for populating each tissue and organ. Most tissues
contain a collection of stem and progenitor cells that replace adult cells lost to age or damage. In many
organs, stem cells divide only under unusual conditions such as in response to injury. In other organs
characterized by rapid turnover, such as the gastrointestinal tract, stem cells regularly divide to replace
worn or damaged cells as part of normal tissue homeostasis.119 In the endometrium, the vast majority of
cells are lost every month, making the need for frequent stem cell division more acute and essential.
Totipotent, pluripotent, and multipotent stem cells give rise to many different tissues, whereas tissuespecific stem and progenitor cells give rise to a limited set of differentiated cells in a local environment.
Tissue-specific stem and progenitor cells may give rise to a single cell type or several types of cells that
make up an individual organ. In the endometrium, multiple lines of evidence in mice and humans support
the presence of a population of stem and progenitors that give rise to stromal fibroblasts and another
population that gives rise to epithelia. Much of the current knowledge on endometrial stem cells comes
from the studies in mice, where cell lineages can be traced using molecular tags and reporters, but
understanding of the human endometrium is accelerating as more signatures of stem and progenitor cells in
other organs are identified, investigated, and validated in the endometrium.116, 117, 118,120,121 Although
early and even more recent studies in humans suggest that endometrial stem and progenitor cells are
localized to the basalis layer,122, 123, 124 more recent evidence of stem and progenitor cell markers in the
luminal region suggests a more complex picture of wider dispersal125 because they are in nonmenstruating
species such as the mouse.126 Moreover, recent studies using tracers in the mouse endometrium have
identified stem and progenitor cells that give rise to both epithelial glandular and luminal epithelial
cells,126, 127, 128 whereas other tissue-resident stem and progenitor cells give rise to stromal cells in the
mouse endometrium.128 It is possible that there is a common stem cell that gives rise first to stromal cells
and can also differentiate into a distinct bipotential epithelial progenitor cell, as suggested by studies in
mice showing gene expression evidence of mesenchymal-epithelial transitions (METs)57 and morphologic
evidence of such METs in humans.129 These tissue-resident stem and progenitor cells regenerate the
endometrium after menstruation in each menstrual cycle.
III. Bone marrow–derived stem cells There also exist multipotent stem cells in several tissues that can

divide and differentiate into multiple types of cells and are found in many tissue types. Most notably, bone
marrow hosts both hematopoietic stem cells, which give rise to circulating white blood cells, red blood
cells, and platelets, and mesenchymal stem cells, which give rise to bone, cartilage, and fat.130 Bone
marrow hematopoietic and mesenchymal stem cells are found in the circulation, where they can be
recruited to sites of injury and contribute to tissue repair in ways that are still incompletely understood in
humans.131, 132, 133 In human patients who received bone marrow transplants, allowing donor cells to be
tracked through sex chromosomes or human leukocyte antigen type, early studies reporting that bone
marrow cells differentiated into hepatocytes or other epithelial tissue types are now mostly attributed to
cell fusion or artifactual protocols.133 However, bone marrow fusion to endometrial stromal cells has been
characterized in mice and is rare compared with bone marrow cells directly contributing to endometrial
cell fates.134 Although the ability of mesenchymal stem cells to transdifferentiate broadly into cells in
other tissue types remains controversial,135 convincing evidence from human studies using single-cell
sequencing indicates that bone marrow–derived donor cells differentiate into mature adipocytes—a known
cell fate for mesenchymal stem cells.136 Studies in mice and humans support the idea that bone marrow–
derived stem and progenitor cells also contribute to the reproductive tract, supplementing the resident stem
and progenitor cells. In both the mouse model and in humans, bone marrow–derived cells are incorporated
into the endometrium where they differentiate into endometrial stromal cells, epithelial cells, and
endothelial cells.137,138 The vast majority of bone marrow–derived endometrial cells are stromal cells with
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epithelial cells differentiating slowly and in smaller numbers. Other groups have subsequently confirmed a
bone marrow origin for endothelial cells in the human139 and for stromal and epithelial cells in
mouse,140,141 establishing a potential role of bone marrow in endometrial repair in humans and prompting
human clinical studies aimed at treating endometrial disorders.118 Perhaps because of the depletion after
menstruation, exogenous stem cells may be even more essential in the uterus than in other organs.
Furthermore, increased recruitment and engraftment of these cells to the uterus occur in response to injury
such as hypoxia or inflammation to aid in repair and regeneration.142
IV. Consequences of stem and progenitor cell loss Infection and iatrogenic trauma can lead to

endometrial destruction and loss of progenitor cells, causing failure to regenerate lost tissue and resulting
in permanent damage. Multipotent stem cells circulate to the endometrium and engraft, contributing to the
regeneration of damaged endometrium and mitigating endometrial atrophy, thin endometrium, and
Asherman’s syndrome.143,144 However, these circulating bone marrow–derived stem cells are found in
only very limited numbers in the circulation. In the setting of severe injury, the number of stem cells may
prove insufficient to repair the damage. We have shown that augmented numbers of bone marrow cells in
the circulation can prevent injury to damaged tissue including the endometrium. Transfer of bone marrow
cells to mice after endometrial injury led to subsequently normal fertility, whereas those receiving placebo
had severe infertility because of Asherman’s syndrome. Several case reports and nonrandomized trials
have explored delivery of endometrial stem cells to women with inadequate endometrial development or
Asherman’s syndrome with promising results for this potential novel therapy.145,146 Understanding normal
menstruation and endometrial repair may provide insight into several endometrial pathologies.
We also found that the chemokine CXCL12 attracts bone marrow–derived mesenchymal stem cells to the
endometrium.147 In a mouse model, we found that the administration of CXCL12 to the damaged uterus
can mobilize and recruit stem cells from the bone marrow to the uterus. In a mouse model of Asherman’s
syndrome, intrauterine administration of CXCL12 led to restoration of normal fertility.148,149 Similarly, in
a mouse model of thin endometrium, treatment with either bone marrow supplementation or CXCL12
administration restores normal endometrial architecture and fertility.144 Future therapy for Asherman’s
syndrome may make use of chemokines that mobilize and attract bone marrow cells without the need for
bone marrow stem cell transplantation.
V. Menstruation and potential role of endometrial stem cells in endometriosis Although rapid

endometrial regeneration is essential for reproduction in menstruating species, one of the adverse
consequences of menstruation and a rapidly regenerating endometrium is endometriosis. Menstruation
allows for retrograde menstruation and the possibility of ectopic implantation of endometrial tissue.
Continued menstrual flow regularly feeds the endometriosis and allows for lesion expansion. Retrograde
menstruation of stem cells in particular contributes to the lesions.150 Furthermore, bone marrow stem cells
contribute to the continued growth of endometriosis lesions.138,151 Bone marrow–derived stem cells may
be responsible for those rare endometriosis cases outside of the peritoneal cavity such as endometriosis
occasionally seen in the lungs or brain. The very processes designed to regenerate and repair the
endometrium after menstruation can lead to disease. Here, the circulating stem cells can even lead to
endometriosis in areas where endometrial cells cannot reach even through retrograde menstruation.
Although retrograde menstruation is a well-established cause of endometriosis, in reality endometrial cell
trafficking is common; we have previously shown that stem cells from endometriosis can be found in the
circulation in a mouse endometriosis model.152 Similarly, we have shown that endometrial cells can be
identified in very small numbers in multiple organs not typically associated with endometriosis including
the brain, lung, spleen, and liver.153 This vast cell migration may explain many of the systemic effects of
endometriosis. Women with this disease are more likely to have depression, anxiety, autoimmune disease,
and a lower average body mass index.154 The regenerative ability of endometrium and use of circulating
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stem cells may allow for regeneration after menstruation and enhance fertility; however, it may predispose
menstruating animals to endometriosis and associated disease. Endometriosis can be considered a systemic
disease in which widespread cell trafficking contributes to the pathophysiology.154
VI. Endometrium, stem cells, and pregnancy Finally, endometrium has an essential role in the

establishment of pregnancy. Indeed, many complications throughout pregnancy have their origin at the
time of implantation.155 It is not surprising that stem cells are an important part of endometrial and
decidual function in pregnancy. We recently reported that there is a major flux of bone marrow–derived
stem cells to the uterus in pregnancy.156 These cells differentiate into endothelial cells and decidual cells
that have a functional role in pregnancy. In a mouse model of infertility based on an endometrial
receptivity defect, administration of normal bone marrow can restore fertility and successful pregnancy in
otherwise infertile animals. This leads to the fascinating conclusion that some instances of infertility or
pregnancy loss may be caused by inadequate bone marrow rather than defects in reproductive organs or
gametes. Indeed, one can now include the bone marrow as a key reproductive organ!
VII. Beyond the uterus: menstrual blood–derived stem cells in the context of regenerative medicine

The fast, scarless regenerative power of the endometrium, along with the relatively easy access to
endometrial stem cells from menstrual effluent (see section 4), has spurred efforts to use menstrual blood–
derived endometrial stem and progenitor cells therapeutically for a range of regenerative medicine
applications beyond those in the uterus mentioned previously.157,158 Endometrial mesenchymal stem and
progenitor cells (MSCs)120,124 share many properties with mesenchymal stem cells derived from the bone
marrow, adipose tissue, and other sources.159 Similar to mesenchymal stem cells from these other sources,
they can be readily expanded in culture, show features of differentiation into the canonical mesenchymal
stem cell connective tissues (bone, cartilage, and fat), and produce a range of immunomodulating
cytokines, chemokines, and growth factors.157,159 Reports that mesenchymal stem cells from
endometrium and other sources can transdifferentiate into a variety of nonconnective tissues, including
liver, pancreatic beta cells, and hepatocytes, both in vitro and in animal models or in studies of human
bone marrow transplant patients, have been attributed to experimental artifacts, as described previously
and in section 4.
More than 1000 clinical trials involving human mesenchymal stem cells or their products are currently
listed on ClinicalTrials.gov as of May, 2020, with many in advanced phase III stages of testing. Of these
trials, about 400 are listed as involving autologous cells and about 300 as involving allogeneic cells (others
do not specify in a searchable term; they may involve cell products such as matrix or exosomes). Clinical
applications listed on ClinicalTrials.gov may broadly be divided into direct, permanent regeneration of
connective tissues (bone, cartilage, fat, or related tissues), where autologous cells are required, and
immunomodulatory applications that tilt healing toward regeneration rather than fibrotic repair through
transient action of the therapeutic cells. For example, a phase III clinical trial is underway at the Cleveland
Clinic to treat Crohn’s disease fistulas with allogeneic bone marrow–derived mesenchymal stem cells after
a successful phase III trial outside the United States using adipose-derived mesenchymal stem cells.160
Similarly, advanced clinical trials using allogeneic or autologous bone marrow–derived mesenchymal stem
cells to modulate inflammation are underway for aplastic anemia,161,162 liver,163 lung,164,165 and many
other acute or chronic inflammation pathologies.
Of the mesenchymal stem cell clinical trials listed on ClinicalTrials.gov, only 2 use menstrual blood–
derived cells, both taking place at Zhejiang University in Hangzhou, China: 1 for chronic liver disease166
and 1 for type 1 diabetes. However, because menstrual blood–derived mesenchymal stem cells are an
attractive source for autologous transplant in regeneration of connective tissues in women,157 especially
considering that connective tissue cells exhibit strong sex-based phenotypic differences, several
regenerative applications are advancing through large animal studies. Particularly promising is the
potential for endometrial mesenchymal stem cells to repair pelvic organ prolapse by seeding cells onto
1 8
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degradable scaffolds.
These and other connective tissue applications are moving toward human trials.
Whether the ease of collection of human menstrual effluent–derived stem cells, or performance factors of
these cells, will overcome the established infrastructure that relies on bone marrow, adipose tissue, and
other sources for regenerative medicine or other purposes is difficult to predict, but they are in the running.
VIII. Conclusion In summary, menstruation in humans requires rapid regeneration of endometrium that is

facilitated by stem cells. Stem and progenitor cells in the basalis layer are the major source of new
endometrium each cycle. Bone marrow stem cells are engaged to repair endometrium after damage and are
now known to be functionally important for pregnancy in mice.156 Stem cells play a crucial role in
reproduction. With this stem cells flux comes the possibility of disease related to aberrant endometrial
growth, namely, endometriosis. Endometriosis is a systemic disease of inappropriate stem cell
differentiation. Menstruation is far more complex than a simple loss of endometrium and regrowth—it
requires contributions from stem cells both within the uterus and bone marrow. Menstruation also
predisposes to endometriosis, which also involves far more than just the immediate surroundings of the
uterus where most endometriosis settles.
3C. What does fibroid (leiomyoma) research teach us about endometrial function?
Elnur Babayev, MD; Serdar E. Bulun, MD
I. Pathophysiology of uterine fibroid (leiomyoma) formation and growth Uterine fibroids are extremely

common. More than half of women will develop uterine fibroids by the age of 50 years.72 Patients present
with AUB or pressure symptoms such as pelvic discomfort and pain, constipation, or changes in urinary
habits. Submucosal fibroids are also associated with infertility and early pregnancy loss.167, 168, 169
Fibroids are benign uterine tumors characterized by disordered monoclonal proliferation of uterine smooth
muscle cells embedded in an abundant extracellular matrix. One proposed mechanism of fibroid formation
involves genetic and epigenetic changes in multipotent stem cells in the myometrium that lead to abnormal
proliferation and differentiation. Physiological fluctuations in sex steroid levels with subsequent growth
and involution of myometrial cells during the menstrual cycle make these stem cells vulnerable to
mutations or epigenetic changes and fibroid formation. The genetic, epigenetic, molecular, and paracrine
mechanisms underlying fibroid pathophysiology are highly diverse, which explains the observed variations
in individual tumors’ clinical behavior (growing, stable, or regressing) and response to medications.167,168
Fibroid growth is hormone dependent, and the sex steroids estrogen and progesterone are important
regulators of fibroid growth. Most fibroids decrease in size after menopause, whereas pregnancy can lead
to an increase in the size of fibroids. Both systemic and local estrogen can stimulate fibroid growth, but
local estrogen production through aromatase activity in fibroid tissue seems to play an important role in
fibroid pathophysiology.170, 171, 172 Estrogen induces progesterone receptor expression and progesterone
responsiveness of the tumor. Progesterone has been shown to be essential for fibroid growth in animal
studies.173 Progesterone may regulate fibroid growth indirectly through its action on differentiated smooth
muscle cells, which in turn secrete paracrine molecules that stimulate proliferation of multipotent stem
cells.174,175
II. The role of vasoactive substances and inflammatory molecules in the pathogenesis of abnormal
uterine bleeding secondary to fibroids

Fibroids may interfere with normal endometrial function. In fact, heavy menstrual or irregular bleeding is
the most common clinical presentation of fibroids and can affect the physical, social, and emotional wellbeing of women. The degree of endometrial dysfunction seems to be related to the size and location of the
fibroids. Submucosal fibroids located immediately beneath the endometrium are more likely to disrupt
endometrial integrity and cause AUB. Subserosal fibroids are less likely to do so. Intramural fibroids
represent an intermediate pathology, although large intramural fibroids that distort the endometrial cavity
168 169
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will likely lead to abnormal menstruation.
Dissecting the mechanisms of interaction between
fibroids and endometrium can help us understand menstrual biology and may lead to the development of
novel therapeutic modalities for AUB.
Fibroids are space-occupying lesions that, depending on their size, can place significant mechanical stress
on uterine architecture. Fibroids can increase the amount of bleeding by simply increasing the surface area
of the endometrium. In addition, changes in cell shape and stretch can affect gene expression in the
myometrium and endometrium.176, 177, 178 Large intramural and submucosal fibroids may interfere with
the myometrial contractions that occur during menstruation. These contractions help to evacuate
menstruation material from the uterus and decrease blood loss from endometrial vessels under
physiological conditions; thus, even a small submucosal fibroid can lead to a significant blood loss in these
patients.167
Endothelin 1 (ET-1) is a vasoconstrictor that affects spiral arterioles in the endometrium53 and plays an
important role in myometrial contractility.179 Altered expression levels of ET-1 and endothelin receptors
(ETA-R and ETB-R) in uterine fibroids may interfere with the normal physiological function of the
myometrium during menstruation. Fibroids have higher levels of ETA-R and lower levels of ETB-R than
normal myometrium.180,181 Thus, it may be envisioned that altered endothelin biology induced by a
uterine fibroid may affect the vascular function of the adjacent endometrium, giving rise to its irregular
development or shedding.
Menstruating endometrium is rich in cytokines and prostaglandins. How this inflammatory milieu affects
fibroids and vice versa is an active area of investigation. The composition of inflammatory cells is
different in areas of the endometrium that overlay fibroids compared with distant sites. Perifibroid
endometrium has increased numbers of macrophages in all phases of menstrual cycle; however, the
number of uterine natural killer (uNK) cells is decreased in the secretory phase.182 Prostaglandin F2α
levels are increased in fibroid uteri, which may explain the disordered contractility and increased blood
loss observed in these patients. Moreover, prostaglandin E2 (PGE2), which is produced in the normal
menstruating uterus, affects leiomyoma (fibroid) cells. Normal myometrial cells do not show any changes
in gene expression in response to PGE2, whereas leiomyoma (fibroid) cells demonstrate increased
expression of antiapoptotic microRNAs.183 Celecoxib, a cyclooxygenase 2 inhibitor, reduces the
proliferation rate of leiomyomas (fibroids) through a nuclear factor κB–mediated decrease in expression of
cytokines and growth factors.184 Our understanding of the role of prostaglandins in fibroid pathogenesis
may lead to new therapeutic approaches. Gene expression analysis of endometrial biopsies from women
with HMB has also indicated differential expression of antigen processing pathway genes in women with
and without fibroids.185 Thus, specific molecular pathways might be responsible for abnormal bleeding
associated with fibroids.
III. Growth factors as primary mediators of endometrial dysfunction in fibroid uteri Fibroid uteri

demonstrate rich vascularity and increased venous plexus.168,169 There also seems to be defective
vasoconstriction as evidenced by dilated venous spaces and vasocongestion. Increased angiogenesis is also
apparent in patients with fibroids,181,186 with altered expression of angiogenic growth factors and their
receptors. Variations in the number and type of inflammatory cells, which produce angiogenic factors, in
the endometrium of fibroid uteri may contribute to the differences in the expression of these factors.
Moreover, angiogenic genes are differentially expressed in fibroids, myometrium immediately adjacent to
fibroids, and distant myometrium.168 Fibroids express increased levels of the important angiogenic
molecule basic fibroblast growth factor (bFGF) and endometrium associated with fibroids demonstrates
increased expression of the bFGF receptor, bFGF receptor 1 (FGFR1).186 Increased activity of bFGF
through its receptor represents a possible pathophysiological mechanism underlying increased
angiogenesis in fibroids, which may ultimately contribute to HMB.
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A paracrine interaction between fibroids and the endometrium exists that is not just localized to the
endometrium overlying the fibroid; this interaction has global effects on endometrial function.187 For
example, the Wnt/β-catenin pathway plays an important role in fibroid growth. Activation of this pathway
leads to increased expression of transforming growth factor β3 (TGF-β3), and fibroids demonstrate
increased expression of TGF-β3 compared with normal myometrium. TGF-β3 stimulates smooth muscle
cell proliferation and fibronectin expression.188 Moreover, TGF-β3 affects endometrial receptivity and
decidualization by altering the expression of bone morphogenetic protein 2 receptors.189 This effect is
likely secondary to the decreased expression of homeobox A10 (HOXA10). Removal of intramural, but
not submucosal, fibroids seems to reverse the changes observed in HOXA10 levels.190,191 Interestingly,
endometrium obtained from patients with fibroids demonstrates decreased levels of PAI-1 and
thrombomodulin. Endometrial stromal cells exposed to TGF-β3 in vitro show decreased levels of PAI-1,
antithrombin III, and thrombomodulin.74 These experiments suggest that fibroids affect menstruation by
altering homeostasis in the endometrium. Changes in clotting factor levels may tip the balance toward
anticoagulation, which may at least partially account for the increased bleeding seen in patients with
fibroids.
Taken together, fibroids seem to cause abnormal menstruation by interfering with myometrial contractility,
paracrine signaling (growth factors, prostaglandins, endothelin, angiogenic factors), and hemostatic
regulation (alteration in the expression of clotting factors) in the endometrium. Understanding the
mechanisms of AUB secondary to fibroids will shed light on these endometrial functions in normal
menstruation physiology and may lead to the development of new therapeutics for women with fibroids.
3D. Microbiome of the endometrium
Inmaculada Moreno, PhD; Iolanda Garcia-Grau, MS; Carlos Simon, MD, PhD
I. Introduction Humans have always lived in a microorganism-colonized world, in which microbes,

especially bacteria, exist in clear symbiosis with humans. The concept of a human microbiota refers to the
sum of microorganisms that inhabit the human body, and the number of commensal microbes is estimated
to be the same as the number of human cells.192 Human physiology is influenced by the presence of such
microorganisms through the expression of microbial genes (of which there are several million in total in
contrast to only 23,000 human genes).193 Thus, the human microbiome is considered our second genome
and interacts with the host genome creating what is called a hologenome defining a whole complex
organism and contributing to genetic diversity.194 The balance between host and bacterial cells has been
shaped through evolution, and the microbiota in each body niche has adapted in response to intrinsic (eg,
host genetics) and extrinsic or environmental factors (eg, diet). This individual microbiota constitutes a
critical component of immunity, and thus, colonization by different bacteria may turn this mutualistic or
commensal interaction into a parasitic relationship, predisposing the host to pathologic conditions with
variable severity of symptoms.
II. Role of the microbiota in human health and disease The first evidence that microbes contribute to

health and disease comes from the 17th century when it was shown that bacteria from different body
niches in the same individual are different, and there are different bacterial communities in the same body
site in healthy vs diseased subjects.195 It is now apparent that microorganisms, specifically bacteria, exert
functional roles in our body and communicate with host cells by influencing metabolic function, training
of the host immune system, and modulating drug interactions.196 It is also known from studies in mice and
humans that the profile of microorganisms inhabiting an individual early in life contributes to postnatal
development and adulthood by influencing metabolism, respiratory function, bone growth, and
immunomodulation.197, 198, 199, 200 Several studies have revealed that the gut microbiota also affects
neurodevelopment, thereby affecting an individual’s behavior and cognition and susceptibility to mental
disorders through the gut-brain axis.201,202 More recently, the gut microbiome has been linked to the
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secretion of circulating estrogens, leading to the estrobolome concept (Figure 7). Because estrogens are
implicated in numerous biological processes, disequilibrium of the microbiota may subsequently
contribute to a large variety of estrogen-modulated conditions, including metabolic disorders (eg,
metabolic syndrome, obesity), alterations of female reproductive function, and diseases in women (eg,
polycystic ovary syndrome, endometriosis, endometrial hyperplasia).203
III. The existence of an endometrial microbiota Molecular detection of bacterial communities through

16S rRNA gene sequencing has shown that the human microbiota is related to human health and welfare,
as symbiotic microorganisms colonize every human organ, including the reproductive tissues.204 In adult
women, the vaginal microbiota contributes to 9% of the total bacterial load and is characterized by a high
stability with low richness and diversity indexes.205,206
Highly sensitive detection techniques, for example, the latest sequencing technology applied to
microbiology, permit the study of microbial communities at the molecular level, providing ecological
information about the microbiota of low biomass samples that have traditionally been considered sterile
owing to the inefficiency of culture-dependent methods for isolating some types of bacteria under standard
laboratory conditions.207 It must be noted that low biomass samples are susceptible to being masked by
background bacterial DNA contained in laboratory reagents and equipment.208 For this reason, the
analysis of such samples requires extra caution during handling and manipulation and the simultaneous
analysis of blank controls for monitoring potential contamination.209 The endometrial microbiota is
considered a low biomass microbiota because the total amount of bacteria colonizing the uterine cavity is
102 to 104 times lower than the total bacterial load in the vagina.210,211
The microbiota of the upper reproductive tract was identified by studies applying molecular techniques,
such as quantitative polymerase chain reaction or parallel sequencing, to endometrial, fallopian, and
peritoneal samples (review by Koedooder et al, 2019).212 Recently, the existence of a microbiota
continuum throughout the reproductive tract has also been described. Lactobacillus spp. are the most
frequently identified bacteria in the lower reproductive tract of asymptomatic reproductive-age women, but
the abundance and structure of the microbiota change progressively toward the upper tract.211 To date,
several studies have analyzed the composition of the endometrial microbiome of reproductive-age women
using culture-independent methods. Comparative studies have reported that the endometrial and vaginal
microbiota are similar but not identical in every woman.210,213,214 Routes of endometrial seeding have
been proposed,212 with the most likely route being the ascent of bacteria from the vagina, as supported by
the resemblance of the microbiota in consecutive spatial niches and the identification of Gardnerella
vaginalis biofilms in the endometrial walls of women with bacterial vaginosis (BV).215 Most studies
analyzing the endometrial microbiota agree on reporting Lactobacillus as the most common bacteria
detected in studies using culture-independent techniques, whereas other genera, from the
Bifidobacteriaceae, Comamonadaceae, and Streptococcaceae families, are also commonly found in the
uterine cavity of healthy and fertile women.211, 212, 213,216, 217, 218, 219, 220 However, a recently published
paper shows that although 60% of the analyzed endometrial samples present a detectable microbiota
compared with background controls and different from that in the vagina, rectum, and oral cavity,
Lactobacillus was rarely abundant in this type of sample.221 Because each study used different designs,
types of samples, and sequencing platforms, defining the core endometrial microbiota is challenging; no
consensus has been reached so far regarding the molecular signature of the uterine cavity. In addition to the
investigation of the core endometrial microbiota under physiological conditions, the role of endometrial
microbiota in the origin and maintenance of several gynecologic diseases, including pelvic inflammatory
disease, endometriosis, and cancer, is currently under study.211,222, 223, 224, 225
IV. The impact of the endometrial microbiome on reproductive health outcomes, fertility, and
pregnancy
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Fertility problems can be related to microbial imbalance in the reproductive tract. The cervicovaginal
microbiota of infertile women is more diverse and has lower levels of Lactobacilli (specifically
Lactobacillus iners) and higher levels of BV-associated bacteria (Atopobium vaginae, G vaginalis,
Ureaplasma spp., Leptotrichia, Sneathia) than the microbiota of fertile women.226, 227, 228, 229, 230
Moreover, the abundance of Lactobacillus spp. in vaginal and endometrial samples of infertile patients
undergoing assisted reproductive technology (ART) is significantly lower than that in samples from fertile
volunteers.217
Pregnancy success is affected by the endometrial microbiota as indicated by conventional culture
techniques showing that isolation of bacterial pathogens from the tip of catheters used for embryo transfers
associates with poor reproductive outcomes,231, 232, 233, 234, 235 but the effect of bacteria on human
reproduction is not restricted to the uterine cavity. Microbial culture of ovarian and follicular fluid showed
that isolation of dysbiotic bacteria correlates with higher embryo discard rates and adverse ART success
after in vitro fertilization (IVF), whereas isolation of Lactobacillus spp. associates with better pregnancy
outcomes.236
Our research group has used 16S rRNA sequencing to prospectively investigate the microbiota of
endometrial fluid samples collected from patients undergoing IVF with repeated implantation failure in
relation to their clinical results after embryo transfer.213 Lactobacillus was more abundant in patients with
successful pregnancy compared with those with cycle failure. Interestingly, high Lactobacillus abundance
in endometrial samples was a significant variable for predicting the reproductive success of the patients. In
contrast, low abundance of Lactobacilli together with specific pathogens was associated with poor
reproductive outcomes resulting in implantation failure, biochemical pregnancy, or clinical miscarriage.213
In addition, as an incidental finding, we were able to compare, at the taxonomical and functional level, the
human endometrial microbiota present in a successful fourth-week pregnancy to that of a previous eighthweek spontaneous clinical miscarriage in the same patient with euploid embryos. Bacterial diversity was
lower and Lactobacillus abundance higher (L iners was the only bacterium found) during the healthy
pregnancy.237 These novel observations may profoundly affect our understanding and possible clinical
translation of the microbiome in relation to healthy or pathologic human pregnancy.
V. Reproductive tract microbiome before, during, and after reproductive age Understanding

endometrial microbiota fluctuations during the life cycle and in response to different stimuli will help to
anticipate dysbiotic shifts from the Lactobacillus-dominated physiological state and will allow the design
of novel interventional strategies to restore the endometrial microbial profile. However, because sampling
the endometrium is invasive, longitudinal studies have not yet been published describing the stability of
the endometrial microbiota in the life cycle of healthy, diseased, and infertile subjects. In contrast, the
microbial profile of the vagina, which is easily sampled, has been temporally analyzed. Estrogen levels are
the most critical variable driving vaginal microbiota changes occurring over a life span. Estrogen
modulates the availability of glycogen in the vaginal epithelium and the subsequent growth of Lactobacilli
(Figure 8).238 Because Lactobacillus spp. produce lactic acid, the dominance of the vaginal niche by
Lactobacilli entails the acidification of the niche (where Lactobacillus have a growth advantage), creating
a hostile environment that impedes the growth of pathogens.
In children, the vaginal microbiota is mainly colonized by common aerobic bacteria (ie, Enterobacteria,
Streptococcus, Staphylococcus) and other gram-positive (ie, Actinomyces, Peptostreptococcus) and gramnegative (ie, Veillonella, Bacteroides) anaerobes. Interestingly, Lactobacillus, G vaginalis, and Prevotella
bivia, some of the most representative reproductive tract bacteria in adults, are absent from the vagina
during this period.239,240 Then, coinciding with the estrogen rise at the onset of puberty, the bacterial
profile is reshaped to resemble that of adult women, with increased abundance of Lactobacillus detected in
premenarcheal adolescents. After menarche, the vaginal microbiota is definitively stabilized and obtains
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the reproductive-age microbiota profile with dominance of Lactobacillus clusters in the majority of studied
subjects. Interestingly, G vaginalis levels also rise during puberty in some subjects even before their first
sexual contact.241
The vaginal microbiome of healthy women can be classified in different community state types (CSTs)
based on the structure of bacteria identified. Four CSTs are characterized by the dominance of
Lactobacillus spp., namely, Lactobacillus crispatus (CST I), Lactobacillus gasseri (CST II), L iners (CST
III), and Lactobacillus jensenii (CST V). These 4 clusters associate with vaginal health, whereas a nonLactobacilli microbiota abundant in reproductive tract pathogens, such as G vaginalis, A vaginae,
Dialister, Megasphaera, Prevotella, and Sneathia, is classified as CST IV and associates with BV.242
Colonization and maintenance of microbial populations in the vagina of premenopausal women may be
affected by many factors (eg, age, hormonal milieu, hygiene, menstruation, use of contraceptives, sexual
activity, ethnicity), leading to potential CST shifts over short periods of time or even within 1 menstrual
cycle.242, 243, 244 During pregnancy, the richness and diversity of the vaginal microbiota tend to decrease,
accompanied by increased Lactobacillus, which is consistent with higher levels of estrogens.245, 246, 247,
248
However, dominance of vaginal microbiota by G vaginalis, Ureaplasma, Prevotella, or other
pathogenic taxa during pregnancy associates with complications, mainly preterm birth.249, 250, 251 After
delivery, vaginal bacterial diversity increases and may generally shift to CST IV for up to 1 year
postpartum even for women with high Lactobacillus abundance during pregnancy.248
During menopause, estrogen levels drop, and Lactobacillus spp. levels fall to become 10- to 100-fold less
than in premenopausal women. This occurs with a concomitant increase in Prevotella, Gardnerella,
Atopobium, Ureaplasma, and anaerobic bacteria belonging to CST IV. Interestingly, postmenopausal
women receiving hormone replacement therapy have levels of Lactobacillus similar to those observed
before the menopause.252, 253, 254
VI. Influence of menstruation on the reproductive tract microbiota Hormonal changes within the

menstrual cycle are proposed major regulators of the reproductive tract microbiota. During the menstrual
cycle, circulating estrogens and progesterone positively correlate with community constancy, whereas
during menses, the microbiota is more prone to bacterial changes.243 There are different community trends
during the menstrual cycle with some communities remaining stable across the whole cycle, whereas
others experience CST shifts in response to menses243 and shift back after menstruation. A stable pattern
is observed in some women colonized by L crispatus,255 whereas the majority of women undergo
microbial population changes with menses, entailing transitions from microbiota dominated by
Lactobacillus to microbiota with L iners, G vaginalis, gram-positive cocci, or other dysbiotic
bacteria.256,257
L iners and G vaginalis levels may rise in the vagina during menses because of their capacity to grow
under adverse conditions. For example, G vaginalis cannot grow in iron-limiting conditions but is able to
secrete vaginolysin to lyse host cells (ie, erythrocytes) to gather iron. In addition, some Lactobacillus
strains have protective mechanisms enabling them to grow in the presence of iron. For example, L
crispatus encodes an iron transport system. Similarly, L iners synthesizes a unique iron–sulfur protein
cluster that confers the ability to sequester iron from menstrual blood, providing L iners with an advantage
over L gasseri and L jensenii, within the vaginal niche during menses.255,258,259
At the functional level, fluctuations of the cervicovaginal microbiota have been associated with innate
immunity, HIV acquisition, inflammatory status, and epithelial barrier function.260 For example, women
with G vaginalis showed a sharper decrease of the epithelial barrier protein repetin from the ovulatory to
the luteal phase than women with a Lactobacillus-dominated microbiota.260 However, no studies have
identified yet the relevance of the microbiota for menstrual function or ascertained if the observed changes
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are driven by the cycling sex hormone levels, the microbiota profile, other causing agents, or a
combination. To shed some light on the role of bacterial taxa on menstruation, a recent study has
characterized the endometrial and cervical microbiota of women with AUB at different phases of the
menstrual cycle.261 This study has revealed significant differences in the endometrial microbiota between
women presenting with HMB and dysmenorrhea. Although the endometrial samples of women with
dysmenorrhea presented an increased abundance of Acinetobacter spp., facultative anaerobic genera were
increased in endometrial samples of patients with dysmenorrhea, suggesting a potential contribution of
microbial communities to these menstrual symptoms, although the cause-consequence analysis has yet to
be undertaken.261
VII. Mechanisms for bacterial-host interaction How bacterial cells communicate with their hosts is still

under investigation, but several mechanisms have been proposed. Bacteria can synthesize small molecules
(eg, short-chain fatty acids, proteins, oligosaccharides, vitamins, short noncoding RNAs,
neurotransmitters) that may interact with host cells in several ways, including regulation of the
physicochemical conditions of a niche, epigenetic regulation through proteins interacting with the host
transcriptional machinery, or binding to host receptors (see reviews207,262,263) (Figure 9). Of note, amines
produced by gut bacteria can, owing to their chemical and structural similarity to human endogenous
ligands, effectively bind G protein–coupled receptors (GPCRs), indicating how microbial metabolites
might regulate host functions.264 GPCRs comprise the largest family of receptors in humans and are
responsible for a wide variety of intracellular processes in response to extracellular signals mainly
mediated by hormones, neurotransmitters, or other stimuli. During reproduction, GPCRs are responsible
for responding to neuropeptides and essential hormones, such as gonadotropin-releasing hormone (GnRH),
luteinizing hormone, follicle-stimulating hormone, prostanoids, and others, in the hypothalamus-pituitarygonadal axis.265 This type of host-microbial interaction is of outstanding relevance in pathologic processes
because GPCRs are pharmacologic targets of 35% of approved drugs, and the composition of the
microbiota and its derived products could interfere with drug efficacy. Conversely, up to 25% of
nonantibiotic pharmaceutical drugs designed to target human cells, including antidiabetics,
antidepressants, antipsychotics, and some anti-inflammatory drugs, present antimicrobial activity or alter
the composition of the indigenous microbiota, leading to potential side effects and increasing resistance to
antibiotics.202
VIII. Conclusion The reproductive tract microbiome is currently considered a pivotal player in women’s

health. Further investigation of the underlying mechanisms of host-bacterial interactions is needed to better
understand both physiological and pathologic conditions. Translational implementation of this knowledge
might allow us to shape the microbiome to promote global health using alternative methods and thereby
avoid antibiotic abuse.

4. Menstruation as an Investigative Tool and Diagnostic Resource
Christine N. Metz, PhD; Ridhi Tariyal, MBA, SM; Ji-Yong Julie Kim, PhD; Aoife Kilcoyne,
MBBCh, BAO; Peter K. Gregersen, MD
I. Introduction
The process of menstruation produces a natural tissue biopsy that is arguably underappreciated as a
potential source of rich information on the health status of the endometrium. Growing awareness among
patient populations about menstrual disorders and the advances in mHealth apps, data science, and the
ever-decreasing costs of sequencing are driving new opportunities to characterize normal and pathologic
menstrual functions. Interest in the endometrium as a model of fast, scarless healing for a variety of
regenerative medicine applications further motivates the study of both normal and pathologic menstrual
shedding and regeneration, using both analysis of shed menses and tissue engineering approaches to
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capture complex interactions among epithelia, stromal, immune, and other cell types present in the uterus.
Complementing these approaches, insight into the behaviors of the endometrium in the context of the
uterus in health and disease is achieved with recent advances in imaging technologies.
II. Using menstrual effluent to aid diagnosis of menstruation-associated conditions
Menstrual discharge contains shed endometrium, comprising endometrial epithelial cells, stromal cells,
endothelial cells, and other nonimmune and immune cells together with microbial species present in the
uterus (see section 3D on the microbiome) and vaginal tract along with a vast array of proteins, RNA,
DNA, and metabolites. It is distinctly different from peripheral blood, and its composition aligns closely
with that of the endometrium.266 Because it is considered a waste product discharged from the body, the
term “menstrual effluent” has been used by some investigators (in 41 papers on PubMed as of January
2020), whereas others refer to the discharge as menses or menstrual blood.
Menstrual effluent offers many advantages for investigating uterine health compared with endometrial or
uterine tissues collected through surgical biopsies, including noninvasive collection methods, relatively
large sample volumes, and opportunities for repeat collections (within and across cycles). Although these
advantages have been recognized since menstrual cups first became clinically available in the
1950s,267,268 menstrual effluent remains surprisingly understudied, and until recently, only a few sporadic
attempts in small-scale studies have been made to relate properties of the menstrual effluent to disease
states or to use it for disease diagnostics.269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280 Biochemically,
in healthy women, menstrual blood has been shown to have comparable concentrations of steroid
hormones but higher prolactin levels when compared with peripheral blood,269 and proteomics analysis
has revealed more than 300 different proteins in menstrual blood compared with peripheral blood,275
including scores of proteins and molecules involved in wound healing and regeneration.277 Small-scale
investigations of platelets and coagulation proteins in menstrual blood compared with peripheral or uterine
vein blood have thus far given little insight into potential causes of HMB but revealed that menstrual blood
platelets were largely degranulated.270,271 At the cellular level, in healthy women, small studies showed
that the NK cell repertoire in menstrual blood is stable over many menstrual cycles and different from
peripheral blood,276 and menstrual blood has relatively fewer CD16+ monocytes and more NKT cells
compared with peripheral blood.266,279 Extending the immune cell analysis to disease states, a small (38
patients) study reported alterations in immune cell populations in the menstrual blood of women with
fertility disorders.280 Viable shed endometrial tissue collected from menstrual cups has also been studied
to investigate the role of matrix metalloproteinases in endometriosis, although again the studies were pilot
in nature.272, 273, 274
Several current forces support using menstrual effluent for diagnostics. Women are more comfortable with
various forms of hygiene products, including menstrual cups, which are becoming more mainstream for
managing menstruation, potentially allowing for more reproducible collections. At the same time, women
are gravitating toward consumer health and digital recruitment platforms, creating new opportunities for
research and diagnostic development.281,282 Greater awareness of menstrual disorders and gynecologic
diseases is promoted by widespread reporting of personal suffering by celebrities, along with an explosion
of social media platforms engaging patients, thus priming women and adolescents to seek answers for
debilitating gynecology problems. Finally, the growing awareness of the shortcomings of blood-based
biomarkers in the diagnosis of complex, chronic diseases is driving increased interest in proximal tissue–
based approaches.283
Endometriosis affects 6% to 10% of reproductive-age women and is estimated to cost more than $20
billion per year in the United States.284, 285, 286, 287 Endometriosis offers a particularly compelling case
for development of minimally invasive menstrual effluent–based diagnostics. Endometriosis is
characterized by lesions of endometrial-like glands and stromal cells growing outside of the uterus, which
284 28 288
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are often associated with debilitating pain and infertility.284,285,288 Although several theories for its
etiology involve developmental origins,289,290 Sampson’s theory of reflux menstruation into the peritoneal
cavity remains a plausible explanation in light of the clinical presentation observed in most cases of
endometriosis.
Numerous factors likely contribute to a diagnostic delay for endometriosis of up to 7 to 10 years.291, 292,
293
Some women and adolescents experience vague symptoms that overlap with other conditions, whereas
other women and adolescents have few or no symptoms and are not diagnosed until they present with
infertility. In addition, women often experience minimization or dismissal of pain symptoms, more
frequent misdiagnoses related to pain, and gender-related disparities in the treatment of pain when
compared with men.294,295 Although standard magnetic resonance imaging (MRI) or ultrasound imaging
can suggest the presence of endometriomas and a limited number of lesions in other locations, most
patients display no detectable lesions on imaging, thus motivating more invasive investigation of
symptoms The definitive diagnosis of endometriosis requires invasive surgery, a procedure many women
and adolescents delay, avoid, or cannot afford. None of the peripheral blood biomarkers proposed for
diagnosing endometriosis exhibit the accuracy required for clinical use.296
Menstrual effluent also offers a particularly attractive noninvasive diagnostic for endometriosis because
numerous differences between the eutopic endometrium in women with endometriosis compared with
unaffected women have already been cataloged at the cellular and molecular level based on analysis of
biopsies.297, 298, 299 These characteristics prompted the launch of a large-scale study to use cells in
menstrual effluent as a minimally invasive diagnostic for endometriosis. To date, more than 500 women,
with and without endometriosis, have been recruited and enrolled through Research OutSmarts
Endometriosis (ROSE; https://feinstein-northwell-edu.medproxy.hofstra.edu/institutesresearchers/institute-molecular-medicine/robert-s-boas-center-for-genomics-and-human-genetics/roseresearch-outsmarts-endometriosis) and the Genotype and Phenotype Registry,300 respectively. Women
consented to provide samples of menstrual effluent and access to their medical records (including the
pathology reports documenting their diagnosis) and completed health or lifestyle questionnaires. In early
studies, women provided menstrual effluent samples using a reusable menstrual cup (provided by Diva
International). Once menstrual effluent collections and processing methods were standardized, the cellular
composition of menstrual effluent cells was profiled and the menstrual effluent–derived stromal fibroblast
cells were characterized to develop a noninvasive diagnostic for endometriosis.301
As found in previous studies, the menstrual effluent in the ROSE study was observed to be a complex,
heterogeneous mixture of numerous cell populations, with a predominance of hematopoietic and immune
cells.266,279,301 Although the sample size in the initial published study is relatively small (n=14 controls
and 6–8 endometriosis subjects), menstrual effluent samples from endometriosis subjects were
characterized by lower numbers of uNK cells when compared with healthy control subjects.301 Within the
menstrual effluent, stromal cells (comprising <1% of cells) show numerous phenotypic and functional
differences between controls and patients with endometriosis,301 similar to those previously described for
stromal cells isolated from endometrial biopsies.297,302, 303, 304 Additional results from examining the
genetic and functional characteristics of menstrual blood–derived stromal cells support a dysregulated
retinoic acid pathway associated with endometriosis vs controls.301
One of the major barriers of this study was the inability to reliably collect menstrual effluent from women
with pelvic pain using the menstrual cup. In response to this challenge, a novel diagnostic menstrual
collection sponge is being developed for external use. Although this external collection sponge is still in
development to maximize cell yield and collection of noncellular content, the early experience has
considerably simplified menstrual effluent collections from all populations, including adolescents.
Ongoing studies are focusing on (1) refining assay methods to quickly and noninvasively diagnose
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endometriosis with reasonable sensitivity and specificity, (2) implementing a prospective study of women
who provide menstrual effluent samples before diagnostic surgery and then subsequently undergo
laparoscopic surgery to definitively diagnose endometriosis as validation of the predictive power of this
diagnostic test, and (3) enrolling adolescents (>9 years old) with symptoms of endometriosis because this
patient group may greatly benefit from an early diagnostic. If large enough samples sizes are evaluated,
results may identify diagnostic phenotypes or stratify endometriosis subtypes for treatment. Repeated
sampling of menstrual effluent may allow treatment responses to be assessed, if correlates with treatment
response can be identified.
Collection and analysis of live cells in menstrual effluent offer potential for discrimination of patient
subgroups based on the analysis of cell identities and phenotype responses to various stimulations ex vivo
that promote decidualization, proliferation, or progesterone responsiveness that can potentially provide
insight into patient responses to therapies. However, cell isolation, characterization, and culture are a
resource-intensive approach, similar to that employed for amniocentesis or chronic villus sampling. This
method is feasible for research studies but may be challenging to translate into routine clinical practice. By
contrast, stabilization of the molecular constituents in menstrual effluent to allow sample storage and batch
processing offers the possibility of lower-cost, high-information content data regarding cell types present
through highly standardized sequencing approaches. Genomic sequencing data on well-controlled patient
populations are rapidly becoming available not only for the microbiome (see section 3D) but also at singlecell resolution of the endometrium characterization for better disease genotyping.305,306
To both take advantage of and contribute to the increasing availability of genomics data focus on the
endometrial microenvironment, the company NextGen Jane developed a Smart Tampon system to provide
facile access to menstrual effluent for diagnostic assessment of women’s reproductive health using
granular genomic analysis and bioinformatic deconvolution. The Smart Tampon may also be used on
nonbleeding days for sampling the vaginal tract, allowing for a natural enrichment of the various cell types
found in the reproductive tract, depending on day of cycle (ovarian and fallopian tube cells, cervical or
endometrial cells, and vaginal microbiome).
NextGen Jane studies found that transcriptional analysis of menstrual fluid has specific genomic
characteristics that are unique from cervicovaginal and venous blood samples. Analysis of menstrual fluid
has shown that the genomic profile of menstrual blood varies greatly by day of cycle, with nearly 800
genes that are differentially expressed in menstrual blood on heavy flow day (day 2) compared with
venous blood. Day 1 of the menstrual cycle shows little variability to venous blood, compared with day 2
where the greatest differential expression may be observed. In the future, it is hoped that the optimal Smart
Tampon will allow analysis of the genetics, epigenetics, microbiome, and transcriptome at scale.
Methylation sequencing, transcriptomics, small RNA sequencing, microbiome analysis, and exome
sequencing can produce up to 35 gigabytes of data. This platform has the potential to help fulfill the
promise of machine learning and precision medicine for malignant and nonmalignant conditions in
women’s health.
Finally, analysis of menstrual effluent at either cell or genomic levels offers potential to improve clinical
therapies by pointing to new mechanisms that might stratify patients into subgroups for different therapies.
In many cancers, patients are stratified according to molecular markers that are related to the disease
mechanism, prognosis, and response to therapy. For diseases as common as endometriosis, adenomyosis,
and others, it is likely that there are subtypes of patients with different molecular features that might
respond to different therapies.307,308 Compared with cancer, where somatic mutations guide targeted
therapies, the molecular features in endometriosis and adenomyosis are harder to identify because the
presence of somatic mutations is still not well established.309 Menstrual effluent provides both molecular
and cellular materials and, hence, may improve diagnosis and patient stratification toward a particular
therapy.
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III. Tissue engineering and microfluidic approaches to study menstruation phenomena
Paradoxically, one of the most well-studied potential applications of menstrual effluent over the past 30
years is as a source of MSCs for various nonreproductive tract tissue engineering applications. Although
early reports that endometrial MSCs could transdifferentiate into insulin-producing islets,310 cardiac
tissue,311 and other differentiated tissue have not borne out, applications in reconstructing connective
tissues in the reproductive tract still hold promise.312,313 Tissue engineering of the endometrium as a
target of learning about menstruation—defined as growing three-dimensional (3D) models with at least
stromal and epithelial cells present—has percolated at a low level for decades, hindered in part by the
incredible difficulty in expanding and cryopreserving human primary endometrial epithelial cells
compared with the relative ease of growing human primary endometrial stromal cells (even from menstrual
effluent). The landscape changed dramatically in 2017 with publication of 2 papers reporting robust
expansion of human primary endometrial epithelial cells as organoids in basement membrane
Matrigel,314,315 using modifications of protocols established by the Clevers group for expansion of human
intestinal epithelial cells.316 Recently, scaffold-free endometrial organoids comprising both epithelial and
stromal cells from endometrial tissue were established, providing yet another 3D model of the
endometrium to study important paracrine actions between 2 important cell types in response to menstrual
cycle hormones.317,318 These protocols enable creation of tissue banks comprising all the major
endometrial cell types and lay the foundation for an explosion of activity in building models of the
menstrual cycle.
Efforts to grow the endometrium and cells from the endometrium as a means to investigate its
pathophysiology date back almost 100 years, with the earliest efforts targeted at trying to understand
whether Sampson’s hypothesis for retrograde menstruation as a cause for endometriosis could be
substantiated.319 The difficulty of growing epithelial cells—they reportedly grew poorly unless stroma
was abundant, and epithelial cells grew as a sheet to cover the explant—was noted in these early explant
cultures.319 The first 3D coculture of primary human endometrial epithelial and stromal cells, comprising
stroma embedded in a collagen gel, overcoated with basement membrane Matrigel seeded with epithelia,
resulted in a well-differentiated confluent epithelial monolayer with a basement membrane with ciliated
(luminal) and secretory epithelia and was tailored to study blastocyst implantation.320 This model, which
recapitulates hormone receptor expression and morphology, also revealed the changes in uterine
receptivity that occurred with mifepristone compared with levonorgestrel.321 An alternate model
employing decellularized human endometrium reseeded with stromal cells and epithelial glands showed
hormone responsiveness over a 28-day cycle by secreting prolactin and IGFBP1, but it was unclear
whether a monolayer with endometrial epithelial morphology was achieved.322 The creation of
multicellular endometrial organoids with polarized epithelial cells surrounding stromal cells provided a
model to study paracrine interactions between 2 important cell types of the endometrium in response to
hormones.317,318 Although several implantation and cell cross talk models have been developed with
endometrial cell lines,323, 324, 325, 326, 327 the profound differences in production of cytokines and growth
factors by cell lines and primary cells call into question the utility of such models.328 However, a cell line–
based model comprised of stromal cells embedded in hormone cues: degradation and breakdown of tissue
were observed in response to the withdrawal of decidual levels of progesterone.329 The intricate cross talk
between endometrial stromal and epithelial cells in driving hormone responses during menstruation has
prompted efforts to create synthetic extracellular matrices for the coculture of endometrial stromal and
epithelial cells in 3D. These matrices allow gentle dissolution of the extracellular matrix to release local
cytokines and growth factors into the local pericellular environment and formation of confluent, stable
epithelial monolayer in coculture with an underlying stroma.326,328 Although these approaches have not
yet directly been applied to menstrual tissues, they are poised for this application.
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A crucial missing element in 3D culture models of the endometrium needed for menstruation is
microvasculature, which provides initial signals for decidualization330 and regulates oxygenation cues
important for tissue breakdown and repair.58 Such models are on the horizon, as several microfluidic
culture models of microvascular networks have been developed for studies of immune cell-microvascular
interactions, tumor cell extravasation and growth, and blood-brain barrier.331, 332, 333, 334, 335 Recently,
approaches to using these models as foundations for mucosal barriers have been described. Apart from the
intrinsic interest in menstruation, the interest in endometrium as a model of fast scarless healing and tissue
repair277 has created momentum for applying these types of models to menstruation, in hopes of gaining
broader insights into regenerative processes.
Finally, microfluidic approaches allow the integration of multiple so-called “microphysiological systems”
(MPSs) or 3D models representing part of a tissue or organ on a microscale. Integrated systems allow the
investigation of systemic effects, including hormonal and other factors that might influence menstruation.
An enabling technology for such integration is a now-commercialized onboard microfluidic pump, first
used to drive long-term culture of 3D liver tissue336,337 and adapted to study gut-liver interactions338,339
and ultimately an integrated platform supporting 10 different interconnected MPSs communicating in a
common culture medium for a month,340 including a 3D endometrium.328 This platform pumping
technology was also adapted to build a model of interconnected 3D units of ovarian, fallopian, uterine,
cervical, and liver tissues integrated into a single communicating fluidic system,341 allowing the
assessment of up to 5 different types of tissues at a time over a menstrual cycle mimic. These cultured
MPSs are responsive to ovarian hormones, and when combined with other tissues, hormones responses
were amplified.341 As observed in other interacting-MPS studies, paracrine actions between tissues
allowed the use of 1 universal medium without compromising the viability of the tissues during this study.
Microfluidic technologies are evolving quickly as the need for user-friendly and affordable systems
becomes evident for the research community. Microfluidics will change the way in vitro studies are
conducted and will allow for new discoveries that will deepen our understanding of uterine biology and
menstruation in a systematic way.
IV. Next-generation uterine imaging
Uterine imaging has been employed to allow for noninvasive methods for diagnosing women’s health
symptoms. Imaging may be used to noninvasively assess conditions of pregnancy and aspects of uterine
health and pelvic health, including endometriosis.342, 343, 344
The indication for pelvic imaging varies by patient age and clinical presentation. Common indications in
premenopausal patients include evaluation for focal endometrial or myometrial lesions (eg, uterine
leiomyoma [fibroids]) in patients with symptoms of AUB and pelvic pain. In postmenopausal patients,
endometrial imaging is often performed to evaluate the endometrium in patients with postmenopausal
bleeding.
Currently, diagnosis relies primarily on anatomic imaging using both ultrasound and MRI that allows for
direct visualization of the endometrium, which is complementary to the previously described techniques,
similarly noninvasive, but allowing for direct visualization of the endometrium in situ, rather than
sloughed endometrial tissue. Ultrasound and MRI may evaluate for the presence of endometrial thickening
and the presence of focal endometrial lesions or polyps. In the evaluation of suspected endometriosis,
transvaginal ultrasound may be used to assess for deeply infiltrating endometrial implants.345 MRI is
useful to map endometrial implants throughout the pelvis, including extrauterine locations, and confers
advantages in terms of the larger field of view, multiplanar capabilities, and excellent contrast
resolution.346,347 A systematic review and meta-analysis (based on the results of 6 studies) compared the
accuracy of transvaginal ultrasound with MRI for diagnosing deep infiltrating endometriosis.343 The
detection of deep infiltrating endometriosis by both MRI and transvaginal ultrasound methods indicated
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similar sensitivities–between 0.59 and 0.85 depending on the site, with greater sensitivity for detection in
the rectosigmoid segment over rectovaginal, uterosacral, and rectovaginal septum locations.343 The
specificities of MRI and transvaginal ultrasound were similar and, similar to sensitivities, showed a wide
range depending on the location.343 It is expected that imaging methods will continue to improve and are
likely to be used in the diagnostic workup for women experiencing symptoms of endometriosis.
Other potential future clinical applications of uterine imaging techniques include early endometrial cancer
detection, distinguishing between leiomyoma and leiomyosarcoma, and assessing cancer response to
treatment. Uterine and pelvic imaging may be combined with the cellular and molecular assessment of
menstrual effluent to help aid in the diagnosis of uterine pathology and for improving the diagnosis of
endometriosis through noninvasive methods.
MRI and ultrasound are modalities currently used for monitoring and predicting response to therapies
offered to reduce menstrual bleeding or achieve amenorrhea before surgical interventions for the
management of AUB. For example, GnRH analogs are used to reduce leiomyoma volume and perfusion.
Contrast-enhanced MRI is used clinically to assess suitability of patients with uterine leiomyoma for
uterine artery embolization and to indicate reductions in perfusion after treatment.348 Applications of T2weighted MRI for estimation of uterine and fibroid volume may be augmented with dynamic contrastenhanced (DCE) MRI for the assessment of tissue perfusion and permeability, and magnetization transfer
(MT) MRI to assess changes in fibrosis and macromolecular content. Such approaches have been explored
extensively in other organs.349,350 There has been limited application of DCE-MRI and MT-MRI in the
assessment of uterine leiomyomas. DCE-MRI has been reported to be sensitive to vascular changes
considered to accompany successful GnRH analog treatment of leiomyomas.351 Future development of
MRI capabilities may offer complementary noninvasive modes to assess treatment responses for menstrual
complaints. Furthermore, evolving MRI techniques during pregnancy that can track fetal motion and
evaluate glucose and oxygen transport across the placenta may provide anatomic and functional
information regarding placental health and fetal well-being.352,353
V. Conclusion
The analysis of menstrual effluent in combination with other new modalities for the understanding of
uterine biology is in the very early stages of development. It is highly likely that the application of new
technologies of genomic and cellular analysis of menstrual effluent and uterine tissues, including singlecell approaches, will yield a deeper understanding of uterine pathophysiology and new and less invasive
methods of diagnosis, including developments for body imaging. These new technologies may be applied
to a variety of uterine health and female reproductive disorders, including endometriosis, uterine
leiomyoma, adenomyosis, and uterine-factor infertility and will thereby aid management strategies for the
symptom of AUB. We hope that these exciting scientific opportunities will catalyze a new era of
collaborative investigation that will correct the past deficit of attention to female reproductive health and
biology.

5. Addressing Menstruation Globally: Progress and Gaps
Marni Sommer, DrPH, MSN; Sandy Clark, MPA
I. Introduction
The global agenda to address menstruation, and specifically menstrual health and hygiene, has gained
significant momentum in recent years, ranging from increasing investment in addressing the menstruationrelated barriers girls in schools in low- and middle-income countries are facing to the more recent
“menstrual equity” and “period poverty” movements spreading across high-income countries. Although
there is growing recognition of menstruation as a relevant issue within public health globally,354 there still
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exist many gaps in the evidence for informing program and policy. Reviewing how the menstruation
agenda has shifted in the last 15 years provides useful insights into how efforts have evolved and what
remains to be done.
II. Shift in menstrual agenda over the last 15 years
In reviewing how the global menstruation agenda has evolved, we explore shifts in the population of
interest, the research and programs underway, the variation in activities by country income status, and the
milestones achieved. There emerge from the analysis 5 periods of time during which distinct efforts were
underway.
Earlier than 2004-2005
Before 2005, multiple efforts were underway exploring or addressing menstruation within global health.
The population of interest included adult women of reproductive age, and in high-income countries, an
interest in the declining age of menarche among girls. Interventions addressing adult women’s
menstruation-related needs were primarily within the clinical realm, such as a focus on reproductive health
and disorders355,356 and the promotion of family planning.357 Although the latter did not address
menstruation as a life course issue, there was attention to the challenges of unscheduled, breakthrough
bleeding among other contributors to contraceptive discontinuation.358. There also existed a rich literature
on menstruation within the social sciences, primarily derived from anthropologists documenting menstrual
traditions and rituals, and its relationship to girls’ and women’s roles within society. In the 1980s and
1990s, in high-income countries in particular, researchers explored girls’ maturation experiences,359, 360,
361
examining the psychological effects of menarche, and the associations of early menarche with girls’
engagement in risky behaviors, such as increased vulnerability to early sexual initiation,362,363
depression,364,365 and substance use.366 Overall, the focus in high-income countries remained on the
individual and the clinical aspects of menstruation.
In contrast, in low- and middle-income countries, there began to emerge a public health lens on
menstruation. Alongside the family planning agenda, there were burgeoning efforts within the water,
sanitation, and hygiene (WASH) field to address menstruation as a challenge faced by girls in school.354
United Nations Children’s Fund (UNICEF) hosted a roundtable event in Oxford aimed at bringing
attention to “menstrual hygiene management” (MHM), a newly coined concept focused on addressing
menstrual management within WASH,367 and the Rockefeller Foundation supported a series of case
studies on sexual maturation in schools in Africa.368 In humanitarian contexts, United Nations High
Commissioner for Refugees recognized the provision of sanitary pads to refugees as part of one of its core
mandates,369,370 providing important recognition of menstruation as a key response aspect.
2005–2011 This window of time brought an increased focus on girls as a population of interest, with a

growing public health approach to menstruation in low- and middle-income countries. More specifically,
important formative research was conducted with girls in and out of school, exploring their first menstrual
experiences, their levels and sources of knowledge about menstruation, and how the onset of menstruation
and puberty might be influencing girls’ education.371, 372, 373 The studies, conducted primarily in Africa
and Asia, suggested that many girls were experiencing their first menstrual period with no previous
information or support, thus feeling confusion, shame, and embarrassment and, for some, a significant fear
that they were ill or dying.374,375 Multiple studies highlighted ongoing taboos, restrictions, and stigma
around menstruation and how menstrual onset and its management negatively affected girls’ abilities to
engage and participate in school.374,376,377 Social and physical barriers included, for example, inadequate
toilets, water and disposal within school grounds, insufficient guidance and support around managing their
menstrual periods, and, for some, a lack of effective menstrual products and underwear.378,379 In response,
a number of interventions emerged, such as the WASH in Schools (WinS) agenda that focused on
380
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380

addressing MHM in schools,
puberty books developed for girls in low-income countries that included
381
content on MHM,
new social entrepreneurs developing improved locally produced menstrual products
382,383
for girls,
and public-private partnerships by global sanitary pad companies focused on improving
access to products.384
2012–2015 Over the next few years, menstruation gained traction as a public health issue for girls in

particular. Although in high-income countries it remained within the clinical realm for girls and women, in
low- and middle-income countries, research documentation of the MHM barriers faced by girls continued,
and pilot trials began to be funded, primarily by the UK Government Medical Research Council, exploring
MHM interventions for adolescent girls in school.385,386 A pilot trial in Kenya included, for example, the
provision of sanitary pads, menstrual cups, and reproductive health information, examining the impact on
the rates of sexually transmitted infections and on reproductive tract infections (BV), unintended
pregnancy, and school attendance and performance.385 A case-control study in India examined women’s
vulnerability to reproductive tract infections in relation to the menstrual cloths or products they used, with
the sample drawn from hospitals.387 Systematic reviews analyzed, for example, the psychosocial and
educational effects of addressing menstruation,388 and a small number of studies explored the impact of
early menarche on rates of infection with herpes simplex virus and HIV and AIDS.389,390 These growing
efforts, particularly those emerging from the water and sanitation arena, contributed to a decision to
include MHM in the lobbying related to the new sustainable development goals (SDGs), with the aim of
having targets and indicators addressing MHM included in the SDGs. This led to the development of a
formal definition for MHM (Box).367

During this period, additional donors began to support projects related to MHM. The Canadian
Government provided funding to UNICEF and the UN Girls Education Initiative to partner with Emory
University on a 14-country WinS for Girls project, which focused on conducting formative MHM research
and developing intervention packages addressing MHM in schools.380 The UK government supported
research on MHM in emergencies, providing funds to the International Federation of the Red Cross to
assess beneficiary preferences around the types of menstrual products (disposable vs reusable) in differing
emergency contexts.391 A new platform arose for sharing learning with the launching of an annual virtual
conference co-organized by the UNICEF and Columbia University showcasing research, practice, and
policy on MHM in schools.392 Funding from the Canadian government also enabled the creation of the
“MHM in Ten” agenda led by the UNICEF and Columbia University, which brought together WASH,
education, SRH, gender, and adolescent health experts to develop a 10-year agenda (2014–2024) aimed at
transforming schools for menstruating girls.393 Additional social entrepreneurs focused on developing
affordable menstrual products, and advocacy campaigns grew around “breaking the silence” on
menstruation, including support for WASH United from the Bill & Melinda Gates Foundation and other
donors to launch an annual global Menstrual Hygiene Day on May 28.394
In addition, new publications began to call attention to the overdue need to explore additional ways in
which menstruation affects girls’ lives, such as the need for data on the average age of menarche in
countries,395 the potential for menarche to be a window of opportunity for engaging girls, their parents or
caregivers, and teachers on health as a step toward subsequent conversations on SRH, including family
planning,396 and for women, their MHM experiences in the workplace.397 A study conducted in India
explored associations between the use and management of menstrual cloths and disposal pads and
reproductive tract infections.387,398 The first resource guidance on MHM, Menstrual Hygiene Matters,
was published with support from the UK government (DFID), recommending approaches for addressing
MHM in development and emergency contexts,399 and UNESCO, with support from Procter & Gamble,
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published a puberty policy document including attention to menstruation and MHM as a key component of
puberty and comprehensive sexuality education.400 There also emerged a stronger articulation of
menstruation as an issue of health and human rights.401
2016–2018 During these years, there has been an exponential growth in attention to the menstruation

agenda in global health. This included increasing resources and attention focused on research and
interventions in low- and middle-income countries, along with a growing awareness that high-income
countries were overdue to address the menstruation-related needs of girls in particular. The population of
interest expanded around the world, with an ongoing focus on girls in and out of school (ages 10–19 years)
but growing recognition that menstruation presents challenges for women and all individuals who
menstruate, such as those with differing gendered identities. The Bill & Melinda Gates Foundation funded
FSG to conduct a global landscape in 2016, An Opportunity to Address Menstrual Health and Gender
Equity, which examined the existing research links between MH and broader health outcomes, social
norms, and education.402 The UK government (Enhanced Learning and Research for Humanitarian
Assistance funding/DFID and Wellcome Trust) supported the International Rescue Committee and
Columbia University to build the evidence on MHM in humanitarian contexts403 and develop the MHM in
Emergencies Toolkit; the latter was launched in 2017, with 27 copublishing humanitarian response
organizations. In 2018, United States Agency for International Development (USAID)/Office of Foreign
Disaster Assistance provided additional funding to the joint team to focus on the menstrual product
disposal, waste management, and laundering needs of displaced populations with the aim of developing
additional evidence and a compendium of practice. There also emerged a growing social and mainstream
media attention. Newsweek and other major outlets published significant stories on menstruation, and the
Period Poverty and Menstrual Equity campaigns emerged, focusing on removing taxes on sanitary
products.404 This growing global movement also introduced new conceptualizations and terminology in
relation to menstruation, which sought to broaden the issue beyond that of the focus on water and
sanitation, such as menstrual health, menstrual health and hygiene, and others. Medical Research Council,
DFID, and Wellcome Trust Joint Global Health Trials have also supported both feasibility pilot and fullscale trial evaluating potential effect of menstrual support on schoolgirls’ SRH and schooling
outcomes.385,386
Research, programming, and policy all expanded during this period. A small number of pilot and full-scale
quantitative studies continued or were initiated in Africa evaluating MHM interventions in
schools,375,385,405 with findings generated on new measures for addressing menstruation. Menstrual
health policies were drafted in multiple countries, such as India, Zambia, and Kenya,385,386,405,406 and in
high-income countries, new legislation began to emerge, such as the Dignity Acts in the United States,
which improve access to menstrual products for incarcerated individuals, and policies focused on
improving access to products in homeless shelters and public schools.407, 408, 409 Despite these important
legislative efforts, limited evidence exists from the United States and other high-income countries on the
actual experiences, including barriers faced, of managing menstruation among girls and the incarcerated
and homeless individuals. However, a small body of evidence is emerging, particularly around the
menstrual management needs of low-income populations in the United States.410 In addition, this window
of time brought an explosion of attention to the provision of menstrual products, with Grand Challenges
Canada, the Case for Her, and other donors supporting the scaling of social entrepreneurial efforts in this
arena such as AfriPads, BeGirl, and others411,412; the launching of new global advocacy and networking
organizations, such as the Menstrual Health Hub, the Menstrual Health Alliance, and the UNFPAsupported African Coalition on Menstrual Health Management; and new regional research capacity
building initiatives, such as the UK Government Global Challenges Research Fund supporting an East
African research group.385,386
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Two challenges that remained included the lack of support from sectors beyond WASH, including limited
attention to menstruation and its relevancy within SRH, education, gender, and other key sectors, and the
limited funding available for furthering the measurement aspects of the menstruation-related agenda that
would enable demonstration of the range of effects of addressing menstruation.
2019 onward Already in 2019, the evidence base and action are growing, with new publications

examining what is known about MHM among populations with disabilities,413 proposed revisions to the
MHM definition to broaden the concept and its measurement beyond the original WASH origins,414
additional systematic reviews,415,416 and ongoing menstrual equity campaigns, global advocacy, and
intervention trials. In an effort to move forward the existing menstruation measurement–related challenges,
including the lack of uptake among other key sectors, a “Monitoring Menstruation” meeting was hosted by
the Columbia University in March 2019 with support from the Water Supply and Sanitation Collaborative
Council that brought together key global monitoring and measurement experts from WASH, gender,
education, and health (sexual and reproductive, psychosocial) to review and find areas of alignment
between the priority outcome and impact measures of these sectoral areas with the progress being made on
menstruation.414 Importantly, USAID provided new funding to explore and pilot interventions addressing
menstruation and women’s economic empowerment.417 However, overall, resources still remain limited
globally to support systematic coverage of all menstruation components, including access to information,
water and sanitation infrastructure, supplies, and related clinical aspects, such as engagement with
healthcare workers well trained on regular and irregular bleeding.
III. Evidence on menstruation globally
As described previously, the early years of the menstruation agenda included the use of primarily
qualitative research methods, given the need for formative research on a sensitive topic about which there
was little documentation from a public health perspective. In recent years, there has been a shift toward
intervention trials, which have brought a rigorous quantitative approach to examining the impact of select
menstruation-related interventions for girls in school in development contexts. Research in emergency
contexts has primarily also been qualitative in nature, including feasibility pilots of guidance and
programmatic response approaches. Funding has remained limited for larger-scale intervention trials that
include attention to water and sanitation in schools, to longitudinal associations between inadequate and
adequate attention to menstruation and SRH and education outcomes, and to the relationship between
menstruation and women’s economic productivity and empowerment in the workplace. In addition, there
has been a growth in national-level data, such as the PMA2020 national surveys incorporating questions
around menstrual management,418, 419, 420 and the inclusion of questions on MHM within UNICEF’s
Multiple Indicator Cluster Surveys in select countries.421 Finally, there exists limited evidence on the
menstruation-related needs and experiences of girls growing up today in high-income contexts and the
MHM challenges faced by low-income and other vulnerable populations in such contexts.
IV. Status of menstruation-related programming and policy
There exists a broad range of menstruation-related programming around the world. This includes, for
example, nongovernmental organizations providing sanitary products, reproductive health or MHM
information, and improvement of water and sanitation facilities in schools, both in development and
emergency contexts. Many national governments, such as South Africa, India, and Kenya, have also begun
subsidizing the provision of sanitary pads (reusable and disposable) to girls in school. In addition, new
innovations are emerging in humanitarian contexts, such as effort by Medicins Sans Frontieres to build
female-friendly washrooms with disposal mechanisms in the health clinics they run in the refugee camps
in Bangladesh hosting Rohingya populations.422 Social entrepreneurs, such as Days for Girls, Sustainable
Health Enterprises, BeGirl, and AfriPads, continue to develop and evaluate the production and distribution
of menstrual products, ranging from reusable pads made by local populations to period underwear.
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As mentioned previously, there has been a growth in menstrual policies around the world. The Uganda
National Bureau of Standards passed one of the first national standards for reusable sanitary pads in
Africa.423 A recent analysis of the existing higher-level education policies in low-income countries
indicated that education sector plans and policies still lack inclusion of attention to menstruation and its
proxies (such as the provision of gender-segregated toilets), which has implications for the inclusion of
budget line items to address the issue in schools424; WASH in Schools–focused menstrual policies provide
important guidance on what interventions are needed but lack sectoral buy-in and financial support. The
Philippines provides an important example with recent policy being incorporated into the country’s
Education Monitoring Information System, providing local-level incentive to include, for example,
improved toilets in schools and the provision of supplies of sanitary pads for emergencies.425 However, as
the “Monitoring Menstruation” meeting held in Geneva in March 2019 indicated, menstruation has yet to
be taken up by other key sectoral programming and policy, such as within SRH, which could improve
attention to anemia in adolescent girls, or the potential for the onset of menstruation to trigger child
marriage.
V. Current and future pathways
Moving forward, there is much left to be done, including addressing the menstruation-related issues faced
by all those who menstruate, such as transmasculine and other populations; menstrual barriers faced in
workplace contexts; recognition that more evidence is needed on vaginal bleeding across the life course,
including the implications for the provision of water, sanitation, supplies, and access to healthcare and
information; improved engagement of healthcare workers on the issue of menstruation in low- and middleincome countries in particular; the important intersection of menstruation and family planning; and
improved measures for monitoring and assessing the impact of menstruation-focused interventions along
with cost-effectiveness studies. Funding support has thus far been limited for addressing this broad
spectrum of issues and for essential intervention and measures-related work that are needed to demonstrate
critical associations between menstruation and population health more broadly. There is an urgent need for
a strong funding stream to assure this impactful work can be done.
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Figure 1

PubMed publications, 1941–2018
A, Search term “Menstruation.” B, Search term “Menstrual Blood.”.
Critchley. Menstruation: science and society. Am J Obstet Gynecol 2020.
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Figure 2

Phylogenetic distribution of menstruating species among eutherian mammals
Lineages in black are from menstruating species, and lineages in white from nonmenstruating species. The lineages with
red outline are the lineages where menstruation originated. Note that there are at least 4 independent originations of
menstruation.
Critchley. Menstruation: science and society. Am J Obstet Gynecol 2020.
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Figure 3

Schematic outline of the experiment by Rudolph et al56 testing the idea that menstruation is a secondary consequence of
spontaneous decidualization
The experiment is conducted with the laboratory mouse, which is a species that under normal conditions is neither
decidualizing nor menstruating. In this species, clitoral or vaginal stimulation during copulation leads to the maintenance
of the corpus luteum even if no pregnancy ensued, leading to pseudopregnancy, as is the case by copulation with a
vasectomized male. Furthermore, it is known that injection of a small droplet of oil into the uterine lumen causes
decidualization. The experiment starts with mating a female to a vasectomized male to induce a pseudopregnancy. At the
morning of the following day, the females are checked for a copulatory plug to verify that copulation has taken place.
Then at day 4 after copulation, a small droplet of oil is injected into the uterus to induce decidualization. Day 4 is the
normal day of implantation in mice. Then the mice are monitored for their level of progesterone and signs of vaginal
bleeding. Progesterone starts to decrease after day 7, and bleeding ensues at about day 9. This experiment shows that
differentiation of the endometrium (decidualization) is sufficient to cause menstruation-like symptoms in a species that
normally does not menstruate.
Critchley. Menstruation: science and society. Am J Obstet Gynecol 2020.
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Figure 4

The modern effect of menstruation
Previously, women experienced menstruation approximately 40 times in their lifetime, owing to pregnancy and lactational
amenorrhea. Women may now expect to have more than 400 episodes of menstruation, mainly as a result of fertility
management. Therefore, AUB is increasingly common. Women may experience significant anemia resulting in a poor
physical quality of life. A negative financial effect occurs because of the cost of managing their blood loss and an inability
to work outside the home. These costs, alongside a loss of caring ability, will have a negative effect on the wider family.
The cost to society through loss of work days and healthcare costs is significant.
AUB, abnormal uterine bleeding.
Critchley. Menstruation: science and society. Am J Obstet Gynecol 2020.
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Figure 5

The PALM-COEIN classification for abnormal uterine bleeding in the reproductive years illustrating the structural
(PALM) and nonstructural causes (COEIN) and as described in Munro et al3,73
Critchley. Menstruation: science and society. Am J Obstet Gynecol 2020.
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Figure 6

Potential mechanisms of “primary” and “secondary” endometrial AUB
As the corpus luteum regresses in the absence of pregnancy, progesterone levels fall. This occurs irregularly in those with
ovulatory or iatrogenic AUB. Progesterone withdrawal causes a local inflammatory response in the endometrium and may
be increased in those with primary endometrial AUB. An increase in vasoactive factors results in intense vasoconstriction
of spiral arterioles to limit blood loss; this may be decreased in primary endometrial AUB. Vasoconstriction may induce
transient tissue hypoxia and stabilization of HIF-1, the master regulator of the cellular response to hypoxia, to coordinate
endometrial repair. There is evidence that this is less intense in those with endometrial AUB. Efficient hemostasis limits
menstrual blood loss at menstruation and this is defective in women with coagulopathy AUB. Structural and nonstructural
pathologies have the potential to disrupt endometrial physiology at menstruation, leading to abnormal uterine bleeding;
these mechanisms remain undefined.
AUB, abnormal uterine bleeding; HIF-1, hypoxia-inducible factor 1.
Critchley. Menstruation: science and society. Am J Obstet Gynecol 2020.
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Figure 7

The estrobolome plays a central role in health and disease through the gut microbiota-estrogen axis
Dysbiosis of gut microbiota may induce systemic inflammation and interferes with estrogen metabolism and receptor
activation in estrogen-regulated organs, influencing neurocognition, metabolism, and the onset of gynecologic diseases
and infertility.
Reprinted from Baker et al.203
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Figure 8

The vaginal microbiome during the life cycle
Bacterial populations inhabiting the vagina change in response to estrogen levels, modulating glycogen availability in the
vaginal epithelium and subsequently the growth of bacteria based on the physicochemical features of the niche at each
phase of the lifecycle.
Reprinted from Muhleisen et al.254
Mod, moderate.
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Figure 9

Potential mechanisms of interaction between endometrial cells and the uterine microbiome
Reprinted from Baker et al.207
AMP, adenosine monophosphate; ROS, reactive oxygen species; SCFA, short-chain fatty acid; TLR, toll-like receptor.
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Box
Definition of MHM (JMP, 2012)
Women and adolescent girls are using a clean menstrual management material to absorb or collect menstrual blood,
that can be changed in privacy as often as necessary for the duration of a menstrual period, using soap and water for
washing the body as required, and have access to facilities to dispose of used menstrual management materials.
They understand the basic facts linked to the menstrual cycle and how to manage it with dignity and without
discomfort or fear.
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